Method for differentiation into retinal ganglion cells from stem cells

ABSTRACT

Provided are a method of preparing retinal ganglion cells by differentiation of stem into retinal ganglion cells, retinal ganglion cells differentiated by the method, a method of screening for a death inhibitor or a proliferation promoter of retinal ganglion cells using the retinal ganglion cells differentiated by the method, a kit of screening for the death inhibitor or the proliferation promoter of retinal ganglion cells including the retinal ganglion cells differentiated by the method, a pharmaceutical composition for treating glaucoma or optic neuropathy including the retinal ganglion cells, a method of treating glaucoma or optic neuropathy including the step of administering the retinal ganglion cells to a subject suspected of having glaucoma or optic neuropathy, and a method of preparing a mature retinal ganglion cell line.

RELATED APPLICATIONS

This application is a national phase application claiming benefit ofpriority under 35 U.S.C. §371 to International (PCT) Patent Applicationserial number PCT/KR2015/009004, filed Aug. 27, 2015, which claimsbenefit of priority to Korean Application 10-2014-0112638, filed Aug.27, 2014. The aforementioned applications are expressly incorporatedherein by reference in their entirety and for all purposes.

TECHNICAL FIELD

The present invention relates to a method of preparing retinal ganglioncells by differentiation of stem cells into retinal ganglion cells,retinal ganglion cells differentiated by the method, a method ofscreening for a death inhibitor or a proliferation promoter of retinalganglion cells using the retinal ganglion cells differentiated by themethod, a kit of screening for the death inhibitor or the proliferationpromoter of retinal ganglion cells including the retinal ganglion cellsdifferentiated by the method, a pharmaceutical composition for treatingglaucoma or optic neuropathy including the retinal ganglion cells, amethod of treating glaucoma or optic neuropathy including the step ofadministering the retinal ganglion cells to a subject suspected ofhaving glaucoma or optic neuropathy, and a method of preparing a matureretinal ganglion cell line.

BACKGROUND ART

Blindness is the medical condition of lacking visual perception. As manyas tens of millions of people, which account for 0.2% to 0.5% of thepopulation of the world, are affected by blindness, and suffer fromgreat losses in personal, social and economical respects. Retinalglaucoma or optic neuropathy is one of the leading causes of blindnessworldwide. Glaucoma is the most common progressive optic neuropathy,leading to irreversible blindness. The global prevalence of glaucoma forpeople over 40 is as high as about 2% to 3%. Globally, there were anestimated 60 million people with glaucoma in 2010. The prevalence ofglaucoma is expected to increase to 80 million by 2020 (Quigley H A andBroman A T, Br J Ophthalmol 2006; 90: 262-267). The prevalence ofglaucoma in the socially active middle-aged generation is 2% to 3%, andit is expected that the number of patients will greatly increase as thepopulation ages, which will become a social and economic burden.Currently, reduction of intraocular pressure is the only method that isclinically applied for glaucoma treatment, but it is known that asignificant proportion of glaucoma patients still progress to blindness.It is known that reduction of intraocular pressure is a conservativemethod capable of merely inhibiting glaucoma progression, and treatmentof the underlying glaucoma is impossible.

Meanwhile, optic neuropathy generally describes optic nerveabnormalities caused by different factors, and includes optic neuritis,ischemic optic neuropathy, toxic or deficiency optic neuropathy,hereditary optic neuropathy, optic atrophy, etc. Among them, thediseases caused by optic nerve degeneration and damage can be helped bystem cell therapy.

Specifically, glaucoma is caused by degeneration and loss of retinalganglion cells (RGCs). After passing through the eye, light is convertedto electric signals in photoreceptor cells, and retinal ganglion cellstransmit these electric signals to the central optic nerve of the brain.

On the other hand, stem cell/regenerative therapy may be the besttherapy for glaucoma and optic neuropathy. A disease caused bydegeneration and loss of a single cell type is a strong target of stemcell therapy. In particular, because the eye is very easily accessiblefor surgical manipulation, and various surgical procedures have beenestablished, there are no difficulties in the application of stem cellsto lesions, and the eye can be a model for the development oftherapeutic drugs.

The goals of stem cell therapy in glaucoma and optic neuropathy are 1)to replace degenerative and damaged RGCs with new RGCs (cell replacementtherapy, neuro-regeneration), 2) to induce therapeutic effects ofanti-inflammation, anti-cell death, neuroprotection, and vascularprotection on degenerative and damaged RGCs as paracrine effects of stemcell therapy, and 3) to select and develop new drugs using stem cellsfor the treatment of glaucoma, for which direct therapeutic agents havenot yet been developed. This therapy may lead to a personalized stemcell therapy using patient-derived pluripotent stem cells. Highlyefficient production of retinal ganglion cells is essential in thedevelopment of therapeutic compositions or models for therapeutic drugs.In particular, there is a problem in that retinal ganglion cellsdegenerated or damaged by diseases cannot be prepared in vitro, andtherefore, it is impossible to develop new drugs for glaucoma and opticneuropathy using normal or abnormal retinal ganglion cells. Therefore,if a large amount of retinal ganglion cells are produced from stemcells, it is possible to create disease models for retinal ganglioncell-associated diseases such as glaucoma and optic neuropathy, andtherefore, drugs for the diseases can be easily developed. Especially,production of RGCs differentiated from patient-derived inducedpluripotent stem cells (iPSC-RGCs) makes it possible to develop newdrugs capable of preventing and inhibiting optic nerve degeneration. Inaddition, the present inventors disclosed a method of differentiatingretinal cells from stem cells in the previous patents (Korean Patent NO.10-1268741 (2013 May 22) and WO2011/043591 (2011 Apr. 14)). However,according to the methods disclosed in the above documents, only about 6%of retinal progenitor cells are differentiated into retinal ganglioncells. Accordingly, there is still a need to develop a differentiationmethod capable of maximizing differentiation into retinal ganglioncells.

DISCLOSURE Technical Problem

The present inventors have tried to produce retinal ganglion cells whichare differentiated from human embryonic stem cells, but they showed poordifferentiation. Accordingly, the present inventors have made manyefforts to develop a new method capable of producing retinal ganglioncells from stem cells. As a result, they developed a method ofdifferentiating human embryonic stem cells into retinal ganglion cellswith a high yield for a short period of time of 5 weeks under chemicallydefined culture conditions without gene implantation or co-culture withretinal tissues. They found that the retinal ganglion cells developedaccording to the method of the present invention are about 200-foldhigher in population than the starting human embryonic stem cells, andthe retinal ganglion cells exhibit excellent neurophysiologicalfunctions, thereby completing the present invention.

Technical Solution

An object of the present invention is to provide a method of preparingmature retinal ganglion cells by differentiation of stem cells intomature retinal ganglion cells, comprising (a) culturing retinalprogenitor cells in a medium containing an IGF1R (insulin-like growthfactor-1 receptor) activator and a Wnt signaling pathway activator todifferentiate them into immature retinal ganglion cells; and (b)culturing the immature retinal ganglion cells in a medium prepared byremoving the Wnt signaling pathway activator from the medium of step (a)and adding the IGF1R activator thereto.

Another object of the present invention is to provide a method ofpreparing mature retinal ganglion cells by differentiation of immatureretinal ganglion cells into mature retinal ganglion cells, including thestep of culturing immature retinal ganglion cells in a medium containingan IGF1R activator and an Shh (sonic hedgehog) signaling pathwayactivator.

Still another object of the present invention is to provide a method ofscreening for a death inhibitor or a proliferation promoter of matureretinal ganglion cells, comprising (a) treating the mature retinalganglion cells obtained and isolated by the above method with a deathinhibitor candidate or a proliferation promoter candidate; and (b)determining that the candidate is a death inhibitor or a proliferationpromoter of mature retinal ganglion cells when the candidate inhibitsdeath of the mature retinal ganglion cells or promotes proliferation ofthe mature retinal ganglion cells, compared to a non-candidate-treatedgroup.

Still another object of the present invention is to provide immatureretinal ganglion cells and mature retinal ganglion cells preparedaccording to the above-described method of the present invention.

Still another object of the present invention is to provide a kit ofscreening for a death inhibitor or a proliferation promoter of matureretinal ganglion cells, including the mature retinal ganglion cells.

Still another object of the present invention is to provide apharmaceutical composition for treating glaucoma or optic neuropathy,including the mature retinal ganglion cells.

Still another object of the present invention is to provide a method oftreating glaucoma or optic neuropathy including the step ofadministering the mature retinal ganglion cells to a subject suspectedof having glaucoma or optic neuropathy.

Still another object of the present invention is to provide a method ofpreparing a mature retinal ganglion cell line, comprising (a) culturingretinal progenitor cells in a medium containing an IGF1R activator and aWnt signaling pathway activator to differentiate them into immatureretinal ganglion cells; and (b) culturing the immature retinal ganglioncells in a medium prepared by removing the Wnt signaling pathwayactivator from the medium of step (a) and adding the IGF1R activatorthereto.

Advantageous Effects

According to the method of the present invention, retinal ganglion cellscan be differentiated from stem cells with a high yield, and the retinalganglion cells obtained by the method can be used in a selection test oftherapeutic agents for diseases such as glaucoma or optic neuropathy andalso used in cell therapy.

DESCRIPTION OF DRAWINGS

FIG. 1A-1B shows cytomorphological microphotographs.

FIG. 1A shows cell floc of human embryonic stem cells in anundifferentiated state (30 passages): after being cultured for 5 daysfrom cells of passage number 29. The cells are typical cell floc ofhuman embryonic stem cells in an undifferentiated state, characterizedby definite separation from adjacent mouse embryonic fibroblast feedercells and having a plain surface and uniform morphology.

FIG. 1B shows floating aggregates, in which the floating aggregates werecultured for 4 days in ultra-low attachment plates after being isolatedfrom the undifferentiated human embryonic stem cell floc of FIG. 1(A).The floating aggregates have spherical morphology, and one floatingaggregate consists of about 292±53 cells.

FIG. 1C-1F shows cytomorphological microphotographs of cellsdifferentiating into retinal ganglion cells.

FIG. 1C shows cells on day 14 after induction of the differentiation:Cell morphology after transferring the floating aggregates topoly-D-lysine/laminin-coated plates and culturing them for 10 daystherein, that is, on day 14 after induction of the differentiation ofthe undifferentiated human embryonic stem cells. It was observed thatthe cells were separated from the floating aggregates and underwentdifferentiation, and had a morphological character of the early stage ofdifferentiation, with meager cytoplasm and round, large nuclei.

FIG. 1D shows cells on day 17 after induction of the differentiation:Cell morphology on day 17 after induction of the differentiation of theundifferentiated human embryonic stem cells. The cells differentiatedwith concomitant active proliferation, and cell flocs under activeproliferation and differentiation formed a round flower-shaped rosetteconfiguration.

FIG. 1E shows cells on day 22 after induction of the differentiation:The cells became richer in cytoplasm and their nuclei were smaller thanthose of FIG. 1(D) as the differentiation progressed. It was observedthat cell flocs differentiated into neurons with short or long neuronalaxons.

FIG. 1F shows cells on day 39 after induction of the differentiation:Most cells differentiated into neurons. With the progress ofdifferentiation into neurons, the cells showed the same cellularity, buthad a mature neuronal shape, compared to those on day 22 after inductionof the differentiation in FIG. 1(E). The nerve cell bodies formed aplurality of clusters, which were connected with each other by longneuronal axons.

*Microscopic field: FIG. 1A-1F (left: 40× magnification; right: 100×magnification).

FIG. 2A-D shows characteristics of induced pluripotent stem cellsreprogrammed from human neonatal foreskin BJ-1 fibroblasts.

FIG. 2A shows phase-contrast microscopic images of human inducedpluripotent stem cells: Cell line after being cultured for 6 days fromcells of passage number 6. The stem cells are characterized by definiteseparation from adjacent mouse embryonic body cells as feeder cells andhaving a plain surface and uniform morphology.

FIGS. 2B and 2C are alkaline phosphatase, Nanog, and SSEA-4 stainingresults showing the characteristics of human embryonic stem cells ofinduced pluripotent stem cells.

FIG. 2D is the result of teratoma assay for evaluating pluripotency ofinduced pluripotent stem cells generated from fibroblasts. At 10 weeksafter transplantation of induced pluripotent stem cells generated fromfibroblasts into the dorsal surface of immunosuppressed SCID mouse,induced pluripotent stem cells developed teratomas with three germlayers of ectoderm (left: neural tissues), mesoderm (middle: cartilage),and endoderm (right: digestive system), indicating pluripotency.

*Scale bar: FIG. 2A-2C: 200 μm.

FIG. 3 is a schematic diagram showing the differentiation of retinalganglion cells from human pluripotent stem cells according to thepresent invention. With reference to embryological development ofretinal ganglion cells, chemically defined medium, adhesion of cells invitro, and differentiation factors were considered at each stage. Stageand period of embryological development were planned based on those ofmice.

FIG. 4 is a schematic diagram showing the differentiation of retinalganglion cells from human pluripotent stem cells according to thepresent invention, which was conducted according to a protocol oftreating Wnt3a for 3 days from day 14 to day 17 after induction of thedifferentiation (referred to as Protocol A). This protocol is aprototype of the protocols of the present invention. The cell type anddifferentiation markers at respective differentiation stages areindicated, and photographs of the cells differentiated according to theprotocol are given in FIG. 1A-1F.

FIG. 5 is a schematic diagram showing the differentiation of retinalganglion cells from human pluripotent stem cells according to thepresent invention, which was conducted according to a protocol oftreating Wnt3a for 3 days from day 11 to day 14 after induction of thedifferentiation (referred to as Protocol B).

FIG. 6 is a schematic diagram showing the differentiation of retinalganglion cells from human pluripotent stem cells according to thepresent invention, which was conducted according to a protocol oftreating Wnt3a for 6 days from day 11 to day 17 after induction of thedifferentiation (referred to as Protocol C).

FIG. 7A-7E shows the results of examining cell marker expressions on day17 after induction of the differentiation of a human embryonic stem cellline H9 according to Protocol A.

FIG. 7A shows cells positive to both of the retinal progenitor cellmarkers, Rax and Pax6, are observed. Retinal progenitor cells have thecharacteristic of being positive to both the markers.

FIG. 7B shows Math5, a marker for immature retinal ganglion cells, isobserved. Compared to the whole cell (DAPI-stained), almost 100% cellsare Math5-positive.

FIG. 7C shows Brn3B, a retinal ganglion cell-specific marker, isobserved in almost all cells. It is indicated that fate of the cells toretinal ganglion cells is determined by Math5, and then they begin todifferentiate into retinal ganglion cells.

FIG. 7D shows all cells are positive to both of Brn3A (green staining:nuclear staining) which is one of the retinal ganglion cell-specificmarkers, and Tuj1 (red staining: also called β-tubulin III) which isspecific to the cytoplasm of the neuronal cell.

FIG. 7E shows about 20% of the cells are positive to both of Islet-1(red: nuclear staining), which is a marker of the subtype of retinalganglion cells, and NF200 (green), which is a neural axon-specificmarker.

*Scale bar: FIG. 7A: 50 μm; FIG. 7B: 200 μm & 50 μm; FIG. 7C to FIG. 7E:100 μm & 50 μm.

Nuclear staining of the whole cell: DAPI (blue staining).

FIG. 8 shows the results of flow cytometry to examine marker expressionson day 39 after induction of the differentiation of a human embryonicstem cell line H9 according to Protocol A (experimental results).

FIG. 9A-FIG. 9J shows the results of examining cell marker expressionson day 39 after induction of the differentiation of a human embryonicstem cell line H9 according to Protocol A.

FIG. 9A-9C shows the retinal ganglion cell-specific markers, FIG. 9APax6, FIG. 9B Brn3B, and FIG. 9C Brn3A observed in FIG. 7A-7E are stillobserved.

FIG. 9D shows almost all cells are positive to both of Brn3A (green:nucleus) and Tuj1 (red: cytoplasmic staining, both axons and dendritesare stained). The number and thickness of neuronal axons and dendritesare increased, compared to the cells on day 17 of FIG. 7A-7E. Axonalspiny process and ring, synaptic interaction between cells, anddendritic arbor and spiny process are observed.

FIG. 9E shows cells positive to both of Islet-1 (red: nucleus) and NF200(green: axon) are observed. The number of axons is increased and amature form is observed, compared to the cells on day 17 of FIG. 7A-FIG.7E.

FIG. 9F shows Brn3B (green) and Tuj1 (red): The majority of cell flocsare positive to both Brn3B and Tuj1, which is retinal ganglioncell-specific staining.

FIG. 9G shows Brn3B (green) and Thy1.2 (red): Nuclear staining for Brn3Band cytoplasmic staining for Thy1.2 are observed, which arecharacteristics of retinal ganglion cells.

FIG. 9H shows Brn3A (green) and Thy1.2 (red): Nuclear staining for Brn3Band cytoplasmic staining for Thy1.2 are observed, which arecharacteristics of retinal ganglion cells.

FIG. 9I shows Map2 (green): Staining of cytoplasm including dendrites isobserved.

FIG. 9J shows results of Western blotting, obtained by reactingantibodies with the lysate of human embryonic stem cell-derived retinalganglion cells on day 39 after induction of differentiation, indicatingretinal ganglion cell-specific proteins.

*Scale bar: FIG. 9A to FIG. 9C: 50 μm; FIG. 9D: 200 μm, 50 μm & 20 μm;FIG. 9E: 100 μm, 50 μm & 20 μm; FIG. 9F: 200 μm & 100 μm; FIG. 9G: 20μm; FIG. 9H: 100 μm; FIG. 9I: 50 μm.

Nuclear staining of the whole cell: DAPI (blue).

FIG. 10A-10H shows the results of examining cell marker expressions onday 59 after induction of the differentiation of a human embryonic stemcell line H9 according to Protocol A.

FIG. 10A shows cells positive to both of Brn3A (green: nucleus) and Tuj1(red: cytoplasmic staining, both axons and dendrites are stained) areobserved. The number and thickness of axons and dendrites are increased,compared to the cells on day 39 of FIG. 8.

FIG. 10B shows Tuj1: Axonal spiny process and ring, synaptic interactionbetween cells, and dendritic arbor and spiny process are observed.

FIG. 10C shows NF200: Dendritic spiny process and axon rings areobserved.

FIG. 10D shows Synapsin1: Synapsin1, which is a representative proteininvolved in neurotransmitter release, is observed in the form offunctionally mature puncta along dendrites in presynaptic vesicles,indicating that synapse interaction with other neurons occurs totransmit neural electric stimuli between cells.

FIG. 10E shows Map2/Vglut1: The majority of presynaptic vesiclesindicated by Synapsin1 of FIG. 10D is glutamatergic vesicles (Vglut1:red). Presence of Vglut1 along Map2-positive dendrites (green) isobserved. Glutamatergic excitatory neurons are produced.

FIG. 10F shows Map2/Vgat: The minority of presynaptic vesicles indicatedby Synapsin1 of FIG. 10D is GABAergic vesicles (Vgat: red). Presence ofVgat along Map2-positive dendrites (green) is observed.

FIG. 10 G shows PSD-95/Map2: Protein formation is observed inpostsynaptic vesicles, and an excitatory synaptic marker PSD-95 isdistributed along dendrites (Map2).

FIG. 10H shows Synapsin1/PSD-95: physical synapses by super resolutionmicroscopy: Synapses between presynaptic Synapsin1 and postsynapticexcitatory PSD-95 are observed. The physical synapses can be identifiedby juxtaposition of presynaptic and postsynaptic vesicle complexes.There are neurotransmitters causing spontaneous excitatory postsynapticcurrents (sEPSCs), which are the electrophysiological characteristic of“mature retinal ganglion cells”, indicating functional maturation ofretinal ganglion cells.

*Scale bar: FIG. 10A: 100 μm; FIG. 10B: 100 μm & 20 μm; FIG. 10C: 20 μm;FIG. 10D: 50 μm & 20 μm; FIG. 10E: 20 μm; FIG. 10F: 20 μm; FIG. 10G: 50μm & 1 μm; FIG. 10H: 2 μm & 0.5 μm.

Nuclear staining of cells: DAPI (blue).

FIG. 11A-11I shows the results of examining cell marker expressions onday 39 after induction of the differentiation of a human embryonic stemcell line H9 according to Protocol B.

FIG. 11A shows Math5

-   -   FIG. 11B shows Brn3B

FIG. 11C shows Brn3A

-   -   FIG. 11D shows, FIG. 11E shows Islet-1 (red: nucleus) and NF200        (green: axon)

FIG. 11F shows NF200

FIG. 11G shows Brn3A, Tuj1

FIG. 11H shows Tuj1

FIG. 11I shows Synapsin1/Tuj1

*Scale bar: FIG. 11A to FIG. 11I: 50 μm. Nuclear staining of FIG. 11H:DAPI (blue).

FIG. 12A-12H shows the results of examining cell marker expressions onday 39 after induction of the differentiation of a human embryonic stemcell line H9 according to Protocol C.

FIG. 12A shows Math5

FIG. 12B shows Pax6

FIG. 12C shows Brn3B

FIG. 12D shows Brn3A

FIG. 12E shows Brn3A, Tuj1

FIG. 12E shows Islet-1 (red: nucleus) and NF200 (green: axon)

FIG. 12G shows TrkB: Expression of TrkB, which is a neurotrophinreceptor marker of mature retinal ganglion cells is observed.

FIG. 12H shows Synapsin1/PSD-95

*Scale bar: FIG. 12A to FIG. 12H: 50 μm.

FIG. 13A-FIG. H shows the results of examining cell marker expressionson day 39 after induction of the differentiation of a human embryonicstem cell line H7 according to Protocol A.

FIG. 13A shows Math5

FIG. 13B shows Brn3B

FIG. 13C shows Brn3A

Characteristic markers of retinal ganglion cells are observed in almostall cells.

FIG. 13D shows Brn3A (green: nucleus) and Tuj1 (red: cytoplasmicstaining, both axons and dendrites are stained).

FIG. 13E and FIG. 13F show Islet-1 (red: nucleus) and NF200 (green:axon)

FIG. 13G shows Synapsin1 (green), Tuj1 (red): A presynaptic markerSynapsin1 is distributed along Tuj1-positive axons.

FIG. 13H shows Synapsin1/PSD-95: The presynaptic marker Synapsin1 andpostsynaptic marker PSD-95 are close to each other, indicatingdifferentiation of H7 cell line into “mature retinal ganglion cells”having mature electrophysiological functions by Protocol A, like H9 cellline.

*Scale bar: FIG. 13A: 50 μm; FIG. 13B and FIG. 13C: 100 μm; FIG. 13D:200 μm; FIG. 13E: 200 μm & 20 μm; FIG. 13F: 100 μm; FIG. 13G: 20 μm;FIG. 13H: 20 μm.

Nuclear staining of FIG. 13E: DAPI (blue).

FIG. 14A-FIG. 14L shows the results of examining cell marker expressionson day 39 after induction of the differentiation of human inducedpluripotent stem cells according to Protocol A.

FIG. 14A shows Math5

FIG. 14B shows Pax6

FIG. 14C shows Brn3B

FIG. 14D shows Brn3A

FIG. 14E shows NF200

FIG. 14F shows Brn3A (red: nucleus) and NF200 (green: axon)

FIG. 14G shows Islet-1 (red: nucleus) and NF200 (green: axon): One ofthe subtypes of retinal ganglion cells is observed.

FIG. 14H shows NF200, Islet-1

FIG. 14I shows Brn3A, Tuj1

FIG. 14I shows Tuj1: Differentiation of axons of mature neurons isobserved.

FIG. 14K shows Synapsin1 (green), Tuj1 (red): A presynaptic markerSynapsin1 is distributed along Tuj1-positive axons.

FIG. 14L shows Synapsin1/PSD-95: The presynaptic marker Synapsin1 andpostsynaptic marker PSD-95 are close to each other, indicatingdifferentiation of human induced pluripotent stem cell line into “matureretinal ganglion cells” having mature electrophysiological functions byProtocol A, like H9 cell line.

*Scale bar: FIG. 14A to FIG. 14C, FIG. 14E to FIG. 14H, FIG. 14J, FIG.14L: 50 μm; FIG. 14D, FIG. 14I: 100 μm; FIG. 14K: 20 μm.

FIG. 15A-FIG. 15C shows the results of electrophysiological analysis onday 39 after induction of the differentiation of human embryonic stemcell line H9 according to Protocol A.

FIG. 15A shows a robust regular-spiking train of action potentials isobserved in response to step current injection (pA) in human embryonicstem cell-derived retinal ganglion cells, indicating that the producedretinal ganglion cells acquired mature electrophysiologicalcharacteristics. In general, as neurons mature, action potentials changefrom a single short spiking to multiple lasting spikings in response tocurrent injection.

FIG. 15B shows voltage-gated sodium channel of human embryonic stemcell-derived retinal ganglion cells: Current responses to stepdepolarizations from a holding potential of −80 mV to +40 mV aresuperimposed. Fast-activating and inactivating inward sodium currentswere completely blocked by applying tetrodotoxin (TTX).

FIG. 15C shows spontaneous excitatory postsynaptic currents (sEPSCs)were detected in human embryonic stem cell-derived retinal ganglioncells without co-culture with other retinal tissues on day 39 afterinduction of the differentiation, indicating that functional excitatorysynapses are formed between human embryonic stem cell-derived retinalganglion cells.

FIG. 16A-FIG. 16E shows the results of electrophysiological analysis onday 59 after induction of the differentiation of human embryonic stemcell line H9 according to Protocol A.

FIG. 16A shows Potassium current: 4-Aminopyridine (4-AP) blocked afast-activating fraction of outward potassium current.

FIG. 16B shows a robust regular-spiking train of action potentials isobserved in response to step current injection (pA) in human embryonicstem cell-derived retinal ganglion cells. The number of spike wasincreased, compared to those on day 39 after induction of thedifferentiation.

FIG. 16C shows a graph for the number of spikes evoked by step currentinjections (pA): The number of spikes increases in proportion tostrength of the current injected.

FIG. 16D shows a staining image of glutamatergic presynaptic vesicles(Vglut1) distributed in dendrites (Map2-positive).

FIG. 16E shows spontaneous excitatory postsynaptic current (sEPSCs): AnAMPA receptor antagonist CNQX blocked the appearance of sEPSCs.Glutamatergic excitatory synapses are formed.

FIG. 17A-FIG. 17B shows the results of electrophysiological analysis onday 96 after induction of the differentiation of human embryonic stemcell line H9 according to Protocol B.

FIG. 17A shows a spiking train of action potentials is observed inresponse to step current injection (pA).

FIG. 17B shows spontaneous excitatory postsynaptic currents (sEPSCs) areobserved. An AMPA receptor antagonist CNQX blocked the appearance ofsEPSCs. Glutamatergic excitatory synapses are formed.

FIG. 18A-FIG. 18B shows the results of electrophysiological analysis onday 66 after induction of the differentiation of human embryonic stemcell line H9 according to Protocol C.

FIG. 18A shows a spiking train of action potentials is observed inresponse to step current injection (pA).

FIG. 18B shows spontaneous excitatory postsynaptic currents (sEPSCs) areobserved. Glutamatergic excitatory synapses are formed.

FIG. 19A-FIG. B shows the results of electrophysiological analysis ofretinal ganglion cells which were matured while supplying adifferentiation medium depleted of IGF-1, Shh, and RA (Retinoic acid) onday 39 after induction of the differentiation of human embryonic stemcell line H9 according to Protocol B.

FIG. 19A shows a robust regular-spiking train of action potentials isobserved in response to step current injection (pA) in human embryonicstem cell-derived retinal ganglion cells on day 96 after induction ofthe differentiation.

FIG. 19B shows a spontaneous excitatory postsynaptic currents (sEPSCs)are observed in human embryonic stem cell-derived retinal ganglion cellson day 96 after induction of the differentiation. Glutamatergicexcitatory synapses are formed.

FIG. 20A-FIG. 20B shows the results of electrophysiological analysis onday 39 after induction of the differentiation of human inducedpluripotent stem cells according to Protocol A.

FIG. 20A shows a robust regular-spiking train of action potentials isobserved in response to step current injection (pA) in human inducedpluripotent stem cell-derived retinal ganglion cells, indicating thatthe produced retinal ganglion cells acquired mature electrophysiologicalcharacteristics.

FIG. 20B shows Potassium current: 4-Aminopyridine (4-AP) blocked afast-activating fraction of outward potassium current.

FIG. 21A-FIG. 21D shows differentiation of human embryonic stemcell-derived retinal ganglion cells by other Wnt signaling pathway andShh receptor activators.

Differentiation was induced according to the time schedule of Protocol Ausing 2 μM of a Wnt signaling pathway activator BIO(6-bromoindirubin-3′-oxime), 50 ng/mL of Norrin, 1 μM of an Shh receptoractivator purmorphamine, and 500 nM of retinoic acid (RA), in additionto Wnt3a used in the above differentiation method. Immunofluorescencestaining results of the retinal ganglion cell markers, Islet-1 (red:nucleus) and NF200 (green: axon) in the cells on day 39 after inductionof differentiation are consistent with the immunofluorescence stainingresults of Wnt3a and Shh.

*Scale bar: FIG. 21A, FIG. 21C, FIG. 21D: 100 μm; FIG. 21B: 50 μm.

FIG. 22 shows the results of analyzing effects of Wnt3a, Shh and RA usedin the Protocol A differentiation method for production of retinalganglion cells. Respective factors were treated according to adifferentiation schedule, and on day 39 after induction ofdifferentiation, an immunofluorescence assay was performed using retinalganglion cell-specific markers.

*Scale bar: 50 μm.

FIG. 23A-FIG. 23B shows cytomorphological microphotographs of humanpluripotent stem cell-derived retinal ganglion cell line aftersubculture. The cells are those of passage number 16 after cell lineestablishment, that is, being cultured for 3 days from cells of passagenumber 15. The subcultured cells of the retinal ganglion cell line showneuronal morphology in vitro.

FIG. 23A shows a morphology of cells subcultured with Medium 1

FIG. 23B shows a morphology of cells subcultured with Medium 2

Both of the cells subcultured with Medium 1 and Medium 2 show a distinctneuronal morphology characterized by cytoplasmic elongation, longneuritis, and phase bright soma.

*left: phase-contrast microscope, 100× magnification; right: 200×magnification.

FIG. 24A-FIG. 24I shows the results of examining cell marker expressionsof human pluripotent stem cell-derived retinal ganglion cell line. Thecells are those of passage number 17 after cell line establishment, andimmunofluorescence staining was performed at 3 days after passaging thecells of passage number 16. The characteristic markers of retinalganglion cells are observed in almost all cells.

FIG. 24A shows Math5

FIG. 24B shows Brn3B

FIG. 24C shows Brn3A/Tuj1

FIG. 24D shows Synapsin1/Tuj1

FIG. 24E shows NF200

FIG. 24F shows KI67

FIG. 24G shows Thy1.2

FIG. 24H shows NMDAR1

FIG. 24I shows TrkB

*Scale bar: FIG. 24A to FIG. 24I: 50 μm. Nuclear staining: DAPI (blue).

FIG. 25 shows microscopic imaging of intracellular calcium in humanpluripotent stem cell-derived retinal ganglion cell line, indicatingthat the cells have neuronal functions. The human embryonic stemcell-derived retinal ganglion cells of passage number 15 were culturedfor 3 days. The cells were treated with 1 μM of fluor-4 and stimulatedwith 1 mM glutamate, and then time differential images were obtained. Asa result, calcium was detected in many live cells. A serial imagespectrum from black (lowest) to white (highest) represents calciumconcentration. In human embryonic stem cell-derived retinal ganglioncells, cytoplasmic calcium is considerably increased in response toglutamate stimulation (head of arrow).

BEST MODE

In order to achieve the above objects, an aspect of the presentinvention provides a method of preparing mature retinal ganglion cellsby differentiation of stem cells into mature retinal ganglion cells,comprising (a) culturing retinal progenitor cells in a medium containingan IGF1R (insulin-like growth factor-1 receptor) activator and a Wntsignaling pathway activator to differentiate them into immature retinalganglion cells; and (b) culturing the immature retinal ganglion cells ina medium prepared by removing the Wnt signaling pathway activator fromthe medium of step (a) and adding the IGF1R activator thereto.

Retina is one of the most well-studied organs in the central nervoussystem of vertebrates, and detailed morphology, synaptic connections ofneurons, and physiological phenomena of retinal neurons have beeninvestigated for decades. On the contrary, structural development ofretinal neurons and various functional mechanisms thereof have not yetbeen clarified.

Of them, “retinal ganglion cells (RGCs)” are the output neurons presentin the retina of vertebrate, and their axons form the optic nerve andsend an image to the brain. A retinal ganglion cell is a neuron, thatis, a nerve cell as the basic unit of the nervous system, and has aplurality of dendrites and a single long fibrous axon. The dendritesform synapses with one another to regulate electrical activity ofneurons and to transmit electrical stimuli that flow into the cell body.The axon has many branching terminals containing granules or vesicleswhich release neurotransmitters in response to nerve stimulation. Asynapse is a point of impulse transmission between neurons. Chemicals,called neurotransmitters, pass through a synaptic gap, and nerve impulseis maintained. During development, retinal ganglion cells are producedfrom multipotent retinal progenitor cells. For example, in mice,development of retinal ganglion cells begins at embryonic day (E) 11.5and continues until postnatal day (P) 0, and reaches a peak at E14.5. Amajor expansion period is known to be between E14.5 and E17.5, which isvariable depending on animals, but is not limited thereto.

The retinal ganglion cells function to transmit visual information fromvarious cells of the retina to the optic nerve center of the brain.Light passed through the eye is converted to electrical signals inphotoreceptor cells, and the electrical signals produced are transmittedto retinal ganglion cells via various neurons of the retina. Retinalganglion cells function to receive these signals and to transmit them tothe optic nerve center of the brain.

Development of retinal ganglion cells is regulated by a hierarchicalgene regulatory network, and development and differentiation aremediated by major transcription factors.

The retinal ganglion cells may be divided into immature retinal ganglioncells and mature retinal ganglion cells according to differentiationdegree.

The “immature retinal ganglion cells” refer to cells that acquirecytomorphological characteristics and protein and genetic markercharacteristics of retinal ganglion cells (Barres, et al., Neuron. 1988;1: 791-803.). The “mature retinal ganglion cells” refer to cells thatare in the mature state as neurons after acquiring the abovecharacteristics of the “immature retinal ganglion cells”. That is, theyhave the morphological characteristics of axonal growth, arbor, andring; dendritic arbor, stratification, and ring; dendritic spinyprocess; synaptic bouton; etc., and the protein and genetic markercharacteristics of presynaptic or postsynaptic protein morphology andvarious receptor characteristics as excitatory nerves. Theelectrophysiological characteristics of the “mature retinal ganglioncells” are formation of spontaneous excitatory postsynaptic currents(sEPSCs), indicating functional maturation capable of forming synapticconnections between retinal ganglion cells (Pfrieger Barres, Science.1997; 277: 1684-7.).

The “immature retinal ganglion cells” refer to cells at an early stageof differentiation from retinal progenitor cells into retinal ganglioncells. These immature retinal ganglion cells are cells that are fated tobe retinal ganglion cells from retinal progenitor cells or cells thatare fated to be retinal ganglion cells, but lack morphological andphysiological characteristics of mature retinal ganglion cells. In thepresent invention, the immature retinal ganglion cells and early retinalganglion cells are used interchangeably.

The “mature retinal ganglion cells” refer to retinal ganglion cells at alate stage of differentiation from retinal progenitor cells into retinalganglion cells or retinal ganglion cells which have alreadydifferentiated. The mature retinal ganglion cells have a physiologicalcharacteristic of producing a high-frequency action potential and amorphological characteristic of having long axons, but are not limitedthereto.

Whether retinal ganglion cells are immature retinal ganglion cells ormature retinal ganglion cells can be determined by identifying theexpression levels of markers specific to respective cells, andmorphological and physiological characteristics thereof (e.g.,electrochemical characteristics).

First, transcription factors playing an important role in developmentand differentiation of retinal ganglion cells are as follows:transcription factors involved in the development of retinal ganglioncells are ATOH7 (Math5), Brn3 family (Brn3A, Brn3B, and Brn3C), and Isl1(Islet-1).

ATOH7, also called Math5, is a factor involved in determining the fateof retinal progenitor cells to retinal ganglion cells, and is essentialfor formation of retinal ganglion cells. Therefore, Math5 is preferablyexpressed in the immature retinal ganglion cells.

Further, POU4F2 and POU4F1 (also called Brn3B and Brn3A, respectively)and Isl1 (Islet-1) downstream of ATOH7 in the gene network are known notto be required for the birth of RGC, but are known to be required forRGC differentiation and survival. They are known to be expressed at anearly stage of differentiation of retinal ganglion cells and alsoexpressed in mature retinal ganglion cells.

In detail, the Brn3 family is involved in regulation of RGCdifferentiation, dendritic stratification of RGCs, and axonal projectionof RGCs during development. Of the Brn3 family, Brn3B is a factorexpressed early during RGC development, and is one of the earliest RGCmarkers, and acts as an important factor in axon growth and survival ofRGCs.

In mice, expression of Brn3A begins at embryonic day (E) 12.5, and inrats, Brn3A is expressed in 92.2% of the RGC population. Brn3B is knownto act in axon formation of RGCs, whereas Brn3A is known to be involvedin dendrite formation.

Isl1 is a homeodomain LIM protein expressed during retina development.Isl1 gene is activated immediately after the birth of RGCs, and itsexpression is identical with that of POU4F2 before the embryonic day (E)14.5. Further, Isl1 is a factor required for RGC differentiation andsurvival, and its expression is governed by ATOH7. Isl1 expression isinitiated at mouse embryonic day (E) 11.5 in completely divided cells,and Isl1 is known to be co-expressed with Brn3B in some ofBrn3B-positive RGC cells.

The above transcription factors play an important role in generation ofretinal ganglion cells, and thus immature retinal ganglion cells mayexpress (1) Math5 and/or (2) one, specifically two, and morespecifically three selected from the group consisting of Brn3B, Brn3Aand Islet1. Further, expressions of these marker genes may be increased,compared to those in retinal progenitor cells, but are not limitedthereto.

Further, the immature retinal ganglion cells may be those expressingNF200 or/and Tuj1. NF200 is a protein called neurofilament 200 kDa, andexpressed at an early stage of differentiation of retinal ganglioncells. Tuj1 is also known to be expressed at an early stage ofdifferentiation of retinal ganglion cells. Therefore, these two genesmay be used to distinguish retinal ganglion cells, specifically, betweenimmature retinal ganglion cells and mature retinal ganglion cells, butare not limited thereto. Additionally, marker genes specific to matureretinal ganglion cells are Thy1.2, TrkB, NMDAR1, Map2, Vglut1, PSD-95,synaptophysin, and synapsin1. These genes are marker genes known to beexpressed in mature retinal ganglion cells.

Therefore, mature retinal ganglion cells may express one, specificallytwo, and more specifically 4, 5, 6, 7, 8, 9 and 10 marker genes selectedfrom the group consisting of Brn3B, Brn3A, Islet-1, NF200, Tuj1, Thy1.2,TrkB, NMDAR1, Map2, Vglut1, PSD-95, synaptophysin and synapsin1, but arenot limited thereto. Further, mature retinal ganglion cells may showhigh expressions of these genes, compared to retinal progenitor cells orimmature retinal ganglion cells, but are not limited thereto.

The method of the present invention is a method capable ofdifferentiating retinal progenitor cells into mature retinal ganglioncells via immature retinal ganglion cells in a high yield, characterizedby culturing retinal progenitor cells in a medium containing a Wntsignaling pathway activator to differentiate them into immature retinalganglion cells, and then culturing the immature retinal ganglion cellsin a medium without the Wnt signaling pathway activator to differentiatethem into mature retinal ganglion cells. That is, technical features ofthe present invention are to determine the fate of stem cells to retinalganglion cells by treatment of stem cells at a specific differentiationstage with the Wnt signaling pathway activator and to differentiate 60%to 95% or more of various retinal cell populations into mature retinalganglion cells by removing the Wnt signaling pathway activator. Thismethod of inducing highly efficient differentiation into mature retinalganglion cells was developed by the present invention for the firsttime.

A detailed description of the method of the present invention will begiven below.

In the method of the present invention, step (a) is a step of culturingretinal progenitor cells in a medium containing an IGF1R activator and aWnt signaling pathway activator to differentiate them into immatureretinal ganglion cells. Step (a) may be performed for 1 day to 10 days,but is not limited thereto.

As used herein, the term “retinal progenitor cell” refers to amultipotent progenitor cell which can differentiate into cells presentin the retina or retinal pigmented epithelial cells. The retinalprogenitor cells are characterized by expressing one, two, or three ormore markers selected from the group consisting of Rax, Pax6, Chx10,Otx2, Sox2, Lhx2, Six3, Six6 and Mitf, and in particular, by expressingone or two of Rax and Pax6, but are not limited thereto.

In connection with retinal development, as mentioned above, retinalprogenitor cells are able to differentiate into various types ofintraretinal cells (rod and cone photoreceptor cells, retinal ganglioncell, horizontal cells, bipolar cells, amacrine cells, Muller glialcells, etc.) and retinal pigmented epithelium, featuring positiveexpression of markers such as Crx, recoverin, rhodopsin, red/greenopsin, blue opsin, peripherin2, PDE6B, SAG, Islet1/NF200, Prox1, PKC-a,Hu C/D, GFAP, ZO-1, and RPE65. However, the expression level andpositive rate of these markers become weaker in retinal progenitor cellsthan in mature retinal cells or retinal pigmented epithelium, but arenot limited thereto.

A medium for differentiation of retinal progenitor cells into immatureretinal ganglion cells is characterized by containing all of the IGF1Ractivator and Wnt signaling pathway activator. Further, the medium fordifferentiation of retinal progenitor cells into immature retinalganglion cells may contain, but is not limited to, a BMP (bonemorphogenetic protein) signaling pathway inhibitor and an FGF(fibroblast growth factor) signaling pathway activator, in addition tothe IGF1R activator and Wnt signaling pathway activator. Further, themedium may be a DMEM/F12 medium containing 1% B27 supplement and 1% N2supplement in addition to the above-described materials, but is notlimited thereto.

As used herein, the term “IGF1R activator” refers to a substance whichactivates IGF-1 (insulin-like growth factor-1) receptor (IGF1R), amember of the tyrosine kinase receptor family. Activated IGF1R interactswith insulin receptor substrates (IRS). In turn, IRS activated by IGF1Racts as an activator of one pathway consisting of PI3K, Akt, and mTOR,and the other pathway consisting of Raf, MEK, and ERK (Ryan & Goss,Oncologist. 2008; 13: 16-24). IGF-1 and IGF-2 fall within the range ofthe IGF1R activator. IGF-1, having a molecular structure similar toinsulin, is implicated in cell growth, cell proliferation,differentiation, and cell death, but is not limited thereto.

Any IGF1R activator may be used without limitation in the presentinvention, as long as it activates IGF1R. It is exemplified by IGF-1 orIGF-2, and specifically, IGF-1, but is not limited thereto.

The medium used for differentiation of retinal progenitor cells intoimmature retinal ganglion cells contains the IGF1R activator in anamount of specifically 0.01 ng/mL to 100 ng/mL, more specifically 0.1ng/mL to 50 ng/mL, much more specifically 1 ng/mL to 20 ng/mL, and mostspecifically 10 ng/mL, but is not limited thereto.

As used herein, the term “Wnt signaling pathway activator” refers to asubstance activating the Wnt signaling pathway which is known toregulate various processes during embryogenesis, including cell fatedetermination, reconstruction of organization, polarity, morphology,adhesion and growth, and the maintenance and proliferation ofundifferentiated cells. Any activator may be included within the Wntsignaling pathway without limitation, as long as it transducesWnt-mediated or β-catenin-mediated signals. The Wnt signaling pathway isa series of processes that are initiated by the binding of a firsttrigger of the Wnt signaling pathway, Wnt, to its receptor or mediatedby the stabilization of β-catenin, which is a downstream target in theintracellular Wnt signaling pathway. The Wnt signaling pathway activatoris, but is not particularly limited to, as follows.

1) By directly adding a Wnt protein: Wnt, a first trigger of the Wntsignaling pathway, is a family of secreted glycoproteins. 19 Wnts havebeen identified: Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b,Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11,and Wnt16b.

2) By increasing the level of β-catenin: Most cells respond to Wntsignaling pathway by an increase in the level of β-catenin. That is, anincrease in dephosphorylated β-catenin level (or the stabilization)means the translocation of β-catenin into the nucleus.

3) By phosphorylation of dishevelled or phosphorylation of aWnt-associated receptor, LRP tail.

4) By using GSK3 (glycogen synthase kinase 3) inhibitors: Lithium (Li),LiCl, bivalent Zn, BIO (6-bromoindirubin-3′-oxime), SB216763, SB415286,QS11 hydrate, TWS119, Kenpaullone, alsterpaullone, indirubin-3′-oxime,TDZD-8, and Ro 31-8220 methanesulfonate salt.

5) By blocking negative regulators of the Wnt signaling pathway, such asAxin and APC, or by using RNAi.

6) With activators of the Wnt pathway, such as norrin and R-spondin2:Norrin binds to Frizzled4 receptor while R-spondin2 interacts withFrizzled8 and LRP6.

7) By gene transfer, including transfection: Either Wnt overexpressionconstructs or β-catenin overexpression constructs may be used.

In the present invention, the Wnt signaling pathway activators may beemployed without limitation as long as it is able to activate the Wntsignaling pathway. They are specifically Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a,Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b,Wnt10a, Wnt10b, Wnt11, Wnt16b; substances increasing β-catenin levels;GSK3 inhibitors such as lithium, LiCl, bivalent zinc, BIO, SB216763,SB415286, CHIR99021, QS11 hydrate, TWS119, Kenpaullone, alsterpaullone,indirubin-3′-oxime, TDZD-8 or Ro 31-8220 methanesulfonate salt; Axininhibitors, APC inhibitors, norrin or R-spondin 2, and morespecifically, Wnt3a, Wnt1, Wnt5a, Wnt11, Norrin, LiCl, BIO or SB415286,but are not particularly limited thereto.

The Wnt signaling pathway activator used for inducing differentiation ofretinal progenitor cells into immature retinal ganglion cells may beused in an amount of 0.01 ng/mL to 500 ng/mL, specifically in an amountof 0.1 ng/mL to 200 ng/mL, and more specifically in an amount of 1 ng/mLto 100 ng/mL, except for LiCl, BIO and SB415286. Among the Wnt signalingpathway activators, the content of LiCl in the medium is 0.1 mM to 50mM, specifically 0.5 mM to 10 mM, and more specifically 1 mM to 10 mM;the content of BIO in the medium is 0.1 μM to 50 μM, specifically 0.1 μMto 10 μM, and more specifically 0.5 μM to 5 μM; the content of SB415286in the medium is 0.1 μM to 500 μM, specifically 1 μM to 100 μM, and morespecifically 5 μM to 50 μM.

As used herein, the term “BMP signaling pathway inhibitor” means a groupof substances capable of inhibiting BMP signaling pathway. BMPs belongto a signaling pathway protein belonging to the TGF-β (transforminggrowth factor-β) superfamily and are involved in early-prenataldifferentiation, prenatal tissue formation, and homeostasis of adulttissues. Extracellular secreted BMPs bind to Type I and Type IIserine/threonine kinase receptors, initiating the BMP signaling pathway.A Type II receptor phosphorylates a Type I receptor. The phosphorylatedType I receptor then phosphorylates the intracellular substrate Smadprotein, mediating the intracellular signal transduction pathway. Smadproteins regulated by receptors are called R-Smads (Receptor regulatedSmad), and Smad-1, 2, 3, 5 and 8 belong to R-Smads. They can bind theintracellular common partner Smad (Co-Smad) Smad-4. They migrate intoand accumulate in the nucleus where they act as transcription factorsand participate in the regulation of target gene expression (Yamamoto &Oelgeschlager, Naturwissenschaften. 2004; 91: 519-34). A BMP signalingpathway inhibitor refers to a substance which blocks the binding ofextracellular BMP to cell-surface receptors. Examples of BMP signalpathway inhibitors include Noggin, chordin, twisted gastrulation (Tsg),cerberus, coco, gremlin, PRDC (protein related to DAN and Cerberus), DAN(differential screening-selected gene aberrative in neuroblastoma),dante, follistatin, USAG-1 (uterine sensitization-associated gene 1),dorsomorphin and sclerostin. By inhibiting BMP signal transduction,Noggin plays a key role in neural induction and in ventralizing dorsalneuroectoderm or mesoderm. Also, Noggin binds to the BMPs, BMP-2, BMP-4and BMP-7, and blocks these BMPs from binding to their receptors(Yanagita, Cytokine Growth Factor Rev. 2005; 16: 309-17).

In the present invention, any BMP signaling pathway inhibitor may beemployed, as long as it is able to inhibit BMP signal transduction.Examples thereof may include Noggin, chordin, twisted gastrulation,cerberus, coco, gremlin, PRDC, DAN, dante, follistatin, USAG-1 (uterinesensitization-associated gene 1), dorsomorphin and sclerostin, but arenot limited thereto. In an embodiment of the present invention, Nogginwas used.

In the present invention, the content of the BMP signaling pathwayinhibitor in the medium for inducing differentiation of the retinalprogenitor cells into immature retinal ganglion cells is 0.01 ng/mL to100 ng/mL, specifically 0.1 ng/mL to 50 ng/mL, more specifically 0.5ng/mL to 20 ng/mL, and most specifically 10 ng/mL, but is not limitedthereto.

As used herein, the term “FGF signaling pathway activator” refers to asubstance capable of inducing or promoting FGF signal transduction. FGFis a factor involved in mitogenesis including cell proliferation andcell differentiation, angiogenesis, bone morphogenesis and neuralinduction. Twenty-two members of the FGF family have been identified sofar. There are four members of the FGF receptor family (FGFR). TheirmRNAs bind to alternatively spliced receptor variants to activate theFGF receptors. Activated FGFR mediates the signal through a Ras/Raf/MeKpathway in the cytoplasm to activate MAP kinase, which in turn inducessignal transduction (Bottcher & Niehrs, Endocr Rev. 2005; 26: 63-77). Ofthe FGF family, FGF2, also known as basic FGF (bFGF), binds mainly toFGFR 1b, FGFR 1c, FGFR 2c, FGFR 3c, and FGFR 44, and strongly activatesFGFR 1c and FGFR 3c. Activators of FGFR 1c and FGFR 3c as well as FGF1,FGF4, FGF8, FGF9, FGF17, and FGF19 may be used as substitutes, but arenot limited thereto.

In the present invention, any FGF signaling pathway activator may beused without limitation, as long as it is able to stimulate FGF signaltransduction. Examples thereof may include an FGFR 1c or FGFR 3cactivator, FGF1, FGF2, FGF4, FGF8, FGF9, FGF17 or FGF19, but are notlimited thereto. In an embodiment of the present invention, FGF2 wasused.

In the present invention, the content of the FGF signaling pathwayactivator in the medium for inducing differentiation of the retinalprogenitor cells into immature retinal ganglion cells is 0.01 ng/mL to100 ng/mL, specifically 0.1 ng/mL to 50 ng/mL, more specifically 1 ng/mLto 20 ng/mL, and most specifically 5 ng/mL, but is not particularlylimited thereto.

Further, the retinal progenitor cells of step (a) may be obtained by(a′) culturing stem cells in a medium containing an IGF1R activator, aWnt signaling pathway inhibitor, and a BMP signaling pathway inhibitorto differentiate them into eye field precursors in the form of floatingaggregates; and (b′) culturing the eye field precursors of step (a′) inthe form of floating aggregates in a medium prepared by supplementingthe medium of step (a′) with an FGF signaling pathway activator todifferentiate them into retinal progenitor cells.

Any stem cells may be used without particular limitation, as long asthey are able to differentiate into retinal progenitor cells, and thestem cells may be selected from the group consisting of bone marrow stemcells (BMS), cord blood stem cells, amniotic fluid stem cells, fat stemcells, retinal stem cells (RSCs), intraretinal Muller glial cells,embryonic stem cells (ESCs), induced pluipotent stem cells (iPSCs), andsomatic cell nuclear transfer cells (SCNTCs).

These stem cells may be differentiated into eye field precursors byculturing them in a medium containing an IGF1R activator, a Wntsignaling pathway inhibitor, and a BMP signaling pathway inhibitor. Inthis regard, the IGF1R activator, the BMP signaling pathway inhibitor,and concentrations thereof are the same as in the above medium used forinducing differentiation into immature retinal ganglion cells

As used herein, the term “Wnt signaling pathway inhibitor” refers to afactor which interrupts interaction between the extracellular Wntprotein and the membrane protein Frizzled receptor or a co-receptor LRP,or inhibits intracellular Wnt-mediated signal transduction. In thepresent invention, any Wnt signaling pathway inhibitor may be usedwithout particular limitation, as long as it inhibits Wnt-mediatedsignal transduction. Examples of the Wnt signaling pathway inhibitorsmay include the Dkk (Dickkopf) family (Dkk-1, Dkk-2, Dkk-3 and Dkk-4),which are antagonists of the co-receptor LRP, Wise, Wnt antagonists(sFRP: secreted Frizzled-related protein) family, a Frizzled-CRD domain,WIF-1 (Wnt inhibitory factor-1), IWP-2, IWP-3, IWP-4, cerberus, Wntantibodies, dominant negative Wnt proteins, overexpression of Axin,overexpression of GSK (glycogen synthase kinase), dominant negative TCF,dominant negative dishevelled or casein kinase inhibitors (CKI-7, D4476etc.), but are not limited thereto. In an embodiment of the presentinvention, Dkk-1 was used.

Further, Wnt signal transduction may be inhibited by suppressing eachcomponent involved in the Wnt pathway, such as RNAi, in addition to theWnt signaling pathway inhibitor.

In the medium, the content of the Wnt signaling pathway inhibitor usedfor differentiating the stem cells into retinal progenitor cells via eyefield precursors may be 0.01 ng/mL to 10,000 ng/mL, but is notparticularly limited thereto.

As used herein, the term “eye field precursor” refers to a cellexpressing specific markers (eye field transcription factors; Zuber, etal., Development, 2003; 130: 5155-67) found in a progenitor for the eyefield of the forebrain neural plate during embryonic development. Theeye field precursors are characterized by expressing one, two, or threeor more markers selected from the group consisting of Six3, Rax, Pax6,Otx2, Lhx2 and Six6, but are not limited thereto.

The eye field precursors have a morphology of floating aggregates. Inthis regard, the floating aggregate refers to a cell mass floating in amedium which is generated when a floc of embryonic stem cells iscultured for at least one day in a non-adhesive plate without feedingmouse embryonic fibroblasts (MEF) and sera. Depending on the compositionof the medium supplied, the eye field precursors may express eye fieldtranscription factors.

Further, step (a′) may be performed for 1 day to 30 days, and step (b′)may be performed for 5 days to 15 days, but are not limited thereto.

In the present invention, the floating aggregates of eye fieldprecursors of step (b′) may be grown adhering to a plate which is coatedwith an extracellular matrix selected from the group consisting ofpoly-D-lysine, laminin, poly-L-lysine, matrigel, agar, polyornithine,gelatin, collagen, fibronectin and vitronectin.

The cell population per floating aggregate which adheres to the plate isthe number of cells which is the most highly efficient. A floatingaggregate of eye field precursors may consist of 200 cells to 400 cells,but is not limited thereto.

Further, the medium of step (a′) may be a DMEM/F12 medium furthercontaining 10% knockout serum replacement and 1% B27 supplement, inaddition to an IGF1R activator, a Wnt signaling pathway inhibitor, and aBMP signaling pathway inhibitor.

Meanwhile, the medium of step (b′) may be a DMEM/F12 medium furthercontaining 1% B27 supplement and 1% N2 supplement, in addition to theabove-described IGF1R activator, Wnt signaling pathway inhibitor, BMPsignaling pathway inhibitor, and FGF signaling pathway activator.

In the method of the present invention, step (b) is a step of culturingimmature retinal ganglion cells which are differentiated in step (a).Immature retinal ganglion cells may be differentiated into matureretinal ganglion cells by step (b).

For highly efficient differentiation into mature retinal ganglion cells,the medium used in step (b) is characterized by containing no Wntsignaling pathway activator which is contained in the medium of step(a).

More specifically, step (b) may be a step of culturing the cells of step(a) in a medium prepared by removing the BMP signaling pathwayinhibitor, the FGF signaling pathway activator, and the Wnt signalingpathway activator from the medium of step (a), and more specifically, ina medium prepared by removing the BMP signaling pathway inhibitor, theFGF signaling pathway activator, and the Wnt signaling pathway activatorfrom the medium of step (a) and adding an Shh (sonic hedgehog) signalingpathway activator thereto.

Further, step (b) may comprise (i) culturing immature retinal ganglioncells in a medium containing the IGF1R activator, the BMP signalingpathway inhibitor, and the FGF signaling pathway activator by removingthe Wnt signaling pathway activator from the medium of step (a); and(ii) culturing immature retinal ganglion cells in a medium prepared byremoving the BMP signaling pathway inhibitor and the FGF signalingpathway activator from the medium of step (i) and adding an Shh (sonichedgehog) signaling pathway activator thereto.

Meanwhile, as used herein, the term “removing” may be interpreted asusing a medium that does not contain a subject to be removed. Also, theterm “a medium whose composition does not comprise X” means all of themedium that does not contain X.

Further, the medium may be a DMEM/F12 medium containing 1% B27supplement and 1% N2 supplement, in addition to the above-describedsubstances, but is not limited thereto.

As used herein, the term “Shh (sonic hedgehog) signaling pathwayactivator” refers to a substance that induces or activates the Shhsignal transduction. Shh is known as a signal transducer associated withthe regulation of various processes during embryogenesis, including cellfate determination, polarity, morphology, proliferation, anddifferentiation (Bertrand & Dahmane, Trends Cell Biol. 2006; 16:597-605). The Shh signaling pathway involves two transmembrane proteins,Ptc (Patched) and Smo (Smoothened). In the absence of Shh, Ptc interactswith and inhibits Smo. On the contrary, in the presence of shh, Shhbinds to Ptc, and Smo is no longer inhibited, leading to Ci/Gli proteinin the cytoplasm entering the nucleus and acting as a transcriptionalactivator for target genes. No particular limitations are imparted tothe Shh signaling pathway activator if it is able to enhance theShh-mediated signaling pathway. Examples of the Shh signaling pathwayactivators may include proteins belonging to the hedgehog family (e.g.,Shh), inhibitors of inhibitory function of Ptc on Smo, Smo receptoractivators, Shh receptor activators (e.g. Hg—Ag, purmorphamine, etc.),substances increasing Ci/Gli family levels, inhibitors of theintracellular degradation of Ci/Gli proteins, and Shh overexpressionconstructs or Ci/Gli overexpression constructs resulting fromtransfection.

In the present invention, any Shh signaling pathway activator may beused, as long as it is able to activate the Shh signaling pathway.Examples thereof may include Shh, Smo receptor activators, inhibitors ofinhibitory function of Ptc on Smo, substances increasing Ci/Gli familylevels, inhibitors of the intracellular degradation of Ci/Gli factors,and an Shh receptor activator, Hg—Ag or purmorphamine, but are notlimited thereto. More specific examples of the Shh signaling pathwayactivator may include Shh and purmorphamine.

In the present invention, the content of the Shh signaling pathwayactivator in the medium used for differentiating immature retinalganglion cells into mature retinal ganglion cells is 0.1 ng/mL to 5,000ng/mL, specifically 1 ng/mL to 2,500 ng/mL, more specifically 10 ng/mLto 1,000 ng/mL, and most specifically 250 ng/mL, but is not particularlylimited thereto.

Step (b) may be performed for 1 day to 200 days.

For highly efficient differentiation into mature retinal ganglion cells,the method may further include the step of (c) culturing the cellscultured in step (b) in a medium prepared by adding RA (retinoic acid)to the medium of step (b).

As used herein, the term “RA (retinoic acid)” refers to a metabolite ofvitamin A, which is a lipophilic molecule. There are two types of RA:all-trans retinoic acid and 9-cis retinoic acid. RA is translocated intothe nucleus where it binds to RARs (retinoic acid receptors) and RXR(retinoid X receptors) respectively and participates in the regulationof target gene transcription, but is not limited thereto.

RA used in the method of the present invention may be trans-retinoicacid and cis-retinoic acid, and the concentration of RA to be used maybe 0.5 nM to 10,000 nM, specifically 5 nM to 5,000 nM, more specifically50 nM to 2,000 nM, and much more specifically 500 nM, but is notparticularly limited thereto.

Step (c) may be performed for 1 day to 120 days, but is not limitedthereto.

The method of the present invention may further include the step of (d)culturing immature retinal ganglion cells or mature retinal ganglioncells in a medium prepared by removing one or more, two or more, orthree selected from the group consisting of an IGF1R activator, Shhsignaling pathway activator, and RA, more specifically, by removing allof the IGF1R activator, Shh signaling pathway activator and RA from themedium of step (c).

According to embodiments of the present invention, although immatureretinal ganglion cells undergoing maturation were cultured in a mediumfree of all of the IGF1R activator, Shh signaling pathway activator, andRA, they showed maturity equivalent to those cultured in a mediumcontaining all of the components.

Further, the method of the present invention may include the step ofdetermining whether the desired cells after the above-described step,for example, immature retinal ganglion cells after step (a), aredifferentiated or not, or determining whether mature retinal ganglioncells after step (b), (c) or (d) are differentiated or not.

Differentiation of the desired cells, specifically, immature retinalganglion cells and mature retinal ganglion cells, may be determined bymeasuring expressions of marker genes specific to the cells, and/or byidentifying morphological characteristics and/or physiologicalcharacteristics.

The measurement of the marker gene expression may be performed bymeasuring the expression level of mRNA or protein of the marker gene,and measurement of the expression level may be performed by usingvarious methods known in the art.

Any technique of analyzing the marker gene expression at an mRNA levelmay be used in the present invention without limitations, as long as itis a method of analyzing mRNA well-known in the art. Examples thereofmay include reverse transcriptase polymerase chain reaction, competitivereverse transcriptase polymerase chain reaction, real-time polymerasechain reaction, Rnase Protection Assay, Northern blotting, and DNA chipassay.

Further, any technique of analyzing the marker gene expression at aprotein level may be used in the present invention without limitations,as long as it is a method of analyzing a protein well-known in the art.Examples thereof may include Western blotting, ELISA, radioimmunoassay,radioimmunodiffusion, Ouchterlony immunodiffusion, rocketimmunoelectrophoresis, immunohistostaining, immunoprecipitation assay,complement fixation assay, FACS, and protein chip assay.

Compared to the pre-differentiative retinal progenitor cells, the matureretinal ganglion cells differentiated according to the present inventionexhibit one or more of the following features: (1) an increasedexpression level of Brn3B; (2) an increased expression level of Brn3A;(3) an increased expression level of Islet1; (4) an increased expressionlevel of NF200; (5) an increased expression level of Tul1; (6) anincreased expression level of Thy1.2; (7) an increased expression levelof TrkB; (8) an increased expression level of NMDAR1; (9) an increasedexpression level of Map2; (10) an increased expression level of Vglut1;(11) an increased expression level of PSD-95; (12) an increasedexpression level of Synaptophysin; and (13) an increased expressionlevel of Synapsin1.

An increase or decrease in the expression levels of the genes may beidentified using antibodies against the proteins encoded by the genes orusing methods well-known to those skilled in the art, such as RT-PCR. Asthey show more of the features, the differentiated cells are defined asbeing closer to the mature retinal ganglion cells. Preferably, themature retinal ganglion cells show one or more, specifically 2 or more,more specifically 3 or more, much more specifically 4 or more, and mostspecifically 5 or more of the features. Preferably, more thanapproximately 40%, 60%, 80%, 90%, 95% or 98% of the population of thecells after differentiation according to the method of the presentinvention have the desired features. Higher ratios are more preferable,but are not limited thereto.

Another aspect of the present invention provides a method ofdifferentiating immature retinal ganglion cells into mature retinalganglion cells, including the step of culturing the immature retinalganglion cells in a medium containing the IGF1R activator and the Shhsignaling pathway activator.

The immature retinal ganglion cells, IGF1R activator, Shh signalingpathway activator, and mature retinal ganglion cells are the same asdescribed above.

The medium which is not applied to the method of differentiatingimmature retinal ganglion cells into mature retinal ganglion cells ischaracterized by containing no Wnt signaling pathway activator.

In the method, the IGF1R activator may be used specifically in an amountof 0.01 ng/mL to 100 ng/mL, more specifically in an amount of 0.1 ng/mLto 50 ng/mL, much more specifically in an amount of 1 ng/mL to 20 ng/mL,and most specifically in an amount of 10 ng/mL, but is not particularlylimited thereto.

In the method, the Shh signaling pathway activator may be used in anamount of 0.1 ng/mL to 5,000 ng/mL, specifically in an amount of 1 ng/mLto 2,500 ng/mL, more specifically in an amount of 10 ng/mL to 1,000ng/mL, and most specifically in an amount of 250 ng/mL, but is notparticularly limited thereto.

Further, the medium may be a DMEM/F12 medium containing 1% B27supplement and 1% N2 supplement in addition to the above-describedsubstances, but is not limited thereto.

The method may further include the step of culturing immature retinalganglion cells in a medium prepared by adding RA (retinoic acid) to themedium containing the IGF1R activator and the Shh signaling pathwayactivator. Herein, “adding” may be interpreted as replacing the previousmedium with a fresh medium containing the above substance together withthe previous medium composition, as well as adding the substance to themedium.

Herein, RA is the same as described above, and the concentration of RAto be used may be 0.5 nM to 10,000 nM, specifically 5 nM to 5,000 nM,more specifically 50 nM to 2,000 nM, and much more specifically 500 nM,but is not particularly limited thereto.

The method may further include the step of culturing immature retinalganglion cells or mature retinal ganglion cells in a medium prepared byremoving one or more selected from the group consisting of an IGF1Ractivator, Shh signaling pathway activator, and RA, and morespecifically, all of the IGF1R activator, Shh signaling pathwayactivator, and RA from the above-described medium.

Still another aspect of the present invention provides immature retinalganglion cells and mature retinal ganglion cells prepared according tothe above-described method of the present invention.

The method, the immature retinal ganglion cells, and the mature retinalganglion cells are the same as described above.

Still another aspect of the present invention provides a method ofscreening for a death inhibitor or a proliferation promoter of matureretinal ganglion cells, comprising (a) treating the mature retinalganglion cells obtained and isolated by the above method ofdifferentiating into mature retinal ganglion cells with a deathinhibitor candidate or a proliferation promoter candidate of matureretinal ganglion cells; and (b) determining that the candidate is adeath inhibitor or a proliferation promoter of mature retinal ganglioncells when the candidate inhibits death of the mature retinal ganglioncells or promotes proliferation of the mature retinal ganglion cells,compared to a non-candidate-treated group.

The method of differentiating into mature retinal ganglion, and themature retinal ganglion cells are the same as described above.

Step (a) is a step of treating the mature retinal ganglion cellsobtained and isolated by the above method of differentiating into matureretinal ganglion cells according to the present invention with a deathinhibitor candidate or a proliferation promoter candidate of matureretinal ganglion cells.

The mature retinal ganglion cells to be treated with the candidate maybe, but is not particularly limited to, mature retinal ganglion cellswhich are differentiated by applying the method of the present inventionto stem cells derived from a healthy person or a patient.

As used herein, the term “death inhibitor of mature retinal ganglioncells” refers to a substance capable of inhibiting death of matureretinal ganglion cells. Specifically, the death inhibitor may include asubstance capable of reducing death of mature retinal ganglion cells, towhich death induction conditions of mature retinal ganglion cells areapplied, compared to those to which the death induction conditions arenot applied. The type of the death inhibitor is not particularlylimited, and the death inhibitor includes compounds, proteins, peptides,and nucleic acids.

As used herein, the term “proliferation promoter of mature retinalganglion cells” refers to a substance capable of inducing or promotingproliferation of mature retinal ganglion cells. Specifically, theproliferation promoter may include a substance capable of increasingproliferation of mature retinal ganglion cells, to which theproliferation promoter is applied, compared to those to which theproliferation promoter is not applied. The type of the proliferationpromoter is not particularly limited, and the proliferation promoterincludes compounds, proteins, peptides, and nucleic acids.

The method of the present invention may include the step of (b)determining that the candidate is a death inhibitor or a proliferationpromoter of mature retinal ganglion cells when the candidate inhibitsdeath of the mature retinal ganglion cells or promotes proliferation ofthe mature retinal ganglion cells, compared to a non-candidate-treatedgroup. Further, the death inhibitor or proliferation promoter of matureretinal ganglion cells may be a therapeutic agent for glaucoma or opticneuropathy.

As used herein, the term “glaucoma” refers to a disease having opticnerve damage accompanied by loss of retinal ganglion cells.

As used herein, the term “optic neuropathy” refers to a diseaseresulting from visual disorders caused by gradual loss of the retinalganglion cells and their axons which constitute the retina. The opticneuropathy includes optic neuritis, ischemic optic neuropathy, toxic ordeficiency optic neuropathy, hereditary optic neuropathy, and opticatrophy.

As described above, glaucoma and optic neuropathy are diseasesaccompanied by loss of retinal ganglion cells, and thus a substancecapable of inhibiting death of retinal ganglion cells or promotingproliferation thereof may be used as a therapeutic agent for glaucoma oroptic neuropathy.

Still another aspect of the present invention provides a kit ofscreening for the death inhibitor or the proliferation promoter ofmature retinal ganglion cells, including the mature retinal ganglioncells prepared by the above-described method of the present invention.Further, the kit may be used for screening of the therapeutic agent forglaucoma or optic neuropathy.

The mature retinal ganglion cells, the death inhibitor, and theproliferation promoter are the same as described above.

The kit may include various tools and/or reagents capable of screeningthe death inhibitor or proliferation promoter of retinal ganglion cellsin addition to mature retinal ganglion cells, which are known in theart. If necessary, the kit may further include a tube for mixing eachcomponent, a well plate, and an instruction manual describing usethereof.

Experimental procedures, reagents, and reaction conditions that may beused in the methods may be those commonly known in the art and will beobvious to those skilled in the art.

Still another aspect of the present invention provides a pharmaceuticalcomposition for treating glaucoma or optic neuropathy, including themature retinal ganglion cells prepared by the above-described method ofthe present invention.

The mature retinal ganglion cells, glaucoma and optic neuropathy are thesame as described above.

For use in the therapeutic composition of the present invention,differentiation of mature retinal ganglion cells from stem cells, forexample, human embryonic stem cells or induced pluripotent stem cells,is induced in vitro, mature retinal ganglion cells are proliferated anddifferentiated in a large amount and then administered to a patienthaving the above disease. The therapeutic composition may be formulatedinto dosage forms general in the art, for example, injectableformulations. The composition may be directly transplanted into aretinal site using a surgical procedure or may be intravenously injectedand migrate to a retinal site. The therapeutic composition of thepresent invention may further include an immunosuppressant to suppressimmune rejection responses to grafts. The composition may furtherinclude a pharmaceutically acceptable carrier. The administration doseof the therapeutic composition of the present invention may varydepending on the severity of the patient, the route, method, andfrequency of administration, the time period of treatment, the patient'sage, sex, and disease severity, and may be easily determined by thoseskilled in the art according to various factors well-known in themedical art.

Still another aspect of the present invention provides a method oftreating glaucoma or optic neuropathy, including the step ofadministering the mature retinal ganglion cells prepared by the methodof the present invention to a subject suspected of having glaucoma oroptic neuropathy.

The method, mature retinal ganglion cells, glaucoma and optic neuropathyare the same as described above.

The mature retinal ganglion cells of the present invention may beadministered to any animal, and the animal may include livestock, suchas cows, pigs, sheep, horses, dogs, mice, rats, cats, etc., as well ashumans and primates.

As used herein, the term “administration” refers to the introduction ofthe composition of the present invention into a subject suspected ofhaving glaucoma or optic neuropathy by a suitable route, including thetransplantation of the differentiated cells. Any administration route bywhich the composition of the present invention reaches a tissue ofinterest may be employed in the present invention. Intraretinalinjection is preferred.

Still another aspect of the present invention provides a method ofpreparing a mature retinal ganglion cell line, comprising (a) culturingretinal progenitor cells in a medium containing the IGF1R (insulin-likegrowth factor-1 receptor) activator and the Wnt signaling pathwayactivator to differentiate them into immature retinal ganglion cells;and (b) culturing the immature retinal ganglion cells in a mediumprepared by removing the Wnt signaling pathway activator from the mediumof step (a) and adding the IGF1R activator thereto.

The medium may further include the Shh signaling pathway activator or RA(retinoic acid), or both.

Further, the method may further comprise separating the cells that arecultured in the medium containing the IGF1R activator and the Shhsignaling pathway activator, and then culturing the cells in (i) amedium containing L-glutamine, mercaptoethanol, andinsulin/transferrin/selenium-X, or (ii) a medium containing L-glutamine,mercaptoethanol, FGF2, IGF-1 and EGF. The medium may specifically be anIMDM medium containing L-glutamine, mercaptoethanol, andinsulin/transferrin/selenium-X, or an IMDM medium containingL-glutamine, mercaptoethanol, FGF2, IGF-1 and EGF. In an embodiment ofthe present invention, Medium 1 containing IMDM, 15% FBS, 1 mML-glutamine, 0.1 mM mercaptoethanol, and 1%insulin/transferrin/selenium-X, and Medium 2 containing IMDM, 15% FBS, 1mM L-glutamine, 0.1 mM mercaptoethanol, 5 ng/mL of FGF2, 10 ng/mL ofIGF-1, and 5 ng/mL of human recombinant EGF were used.

Mode for Invention

Hereinafter, the present invention will be described in detail withreference to Examples. However, these Examples are for illustrativepurposes only, and the invention is not intended to be limited by theseExamples.

Example 1: Culture of Stem Cells

<1-1> Culture of Human Embryonic Stem Cells

Human embryonic stem cell (hESC) lines H9 (WA09, normal karyotype XX)and H7 (WA07, normal karyotype, XX) were purchased from the WiCellResearch Institute (Madison, Wis.).

The human embryonic stem cells were allowed to proliferateundifferentiated (H9 cells: passages 26 to 41; H7 cells: passages 23 to32) by culturing them over feeder cells, such as irradiated mouseembryonic fibroblasts (MEF, Global Stem, Gaithersburg, Md.) ormitomycin-treated mouse embryonic fibroblasts (EmbryoMax Primary MouseEmbryo Fibroblasts, Millipore, Billerica, Mass.) in the followingmedium: embryonic stem cell medium [DMEM/F12 (Invitrogen, Grand Island,N.Y.) liquid, 20% (v/v) KnockOut serum replacement (Invitrogen,Carlsbad, Calif.), 1 mM L-glutamine (Invitrogen), 0.1 mM nonessentialamino acids (Invitrogen), 0.1 mM mercaptoethanol (Sigma-Aldrich, St.Louis, Mo.), 4 ng/mL human recombinant FGF2 (human recombinant basicfibroblast growth factor, Invitrogen)].

While the medium was replaced every day, the undifferentiated stem cells(FIG. 1A) were passaged at a ratio of 1:15 to 1:18 every six or sevendays manually or with collagenase V (collagenase IV, Invitrogen), andthen transferred onto fresh mouse embryonic fibroblast feeder cells.During the passage of the human embryonic stem cells, immunochemicalstaining with OCT-4 and SSEA-4 (Chemicon, Temecula, Calif.), which areantigens specific to undifferentiated human embryonic stem cells, wasconducted at regular intervals of time to monitor the degree ofdifferentiation. Cells that were found to have undergone differentiationwere removed. Meanwhile, the presence of mycoplasma contamination in theembryonic stem cell line, which could have an undesirable effect on thedifferentiation of human embryonic stem cells, was regularly monitoredusing a MycoAlert mycoplasma detection kit (Lonza, Rockland, Me.).

<1-2> Generation and Culture of Human Induced Pluripotent Stem Cell(iPSC)

Human induced pluripotent stem cells were prepared by transfecting stemcell genes (SOX2, KLF4, OCT4, L-MYC, LIN28, and small hairpin RNA forp53) into BJ1 fibroblasts (neonatal foreskin fibroblast, ATCC) usingepisomal plasmid vectors (Okita, Nat method 2011; 8: 409). The humaninduced pluripotent stem cells were allowed to proliferateundifferentiated (passages 5 to 9) by culturing them over feeder cells,such as irradiated mouse embryonic fibroblasts (MEF, Global Stem,Gaithersburg, Md., USA) or mitomycin-treated mouse SNL cells (SNL 76/7cell line, ECACC, Porton Down, UK) in the following medium: embryonicstem cell medium [DMEM/F12 (Invitrogen, Grand Island, N.Y., USA) liquid,20% (v/v) KnockOut serum replacement (Invitrogen, Carlsbad, Calif.,USA), 1 mM L-glutamine (Invitrogen), 0.1 mM nonessential amino acids(Invitrogen), 0.1 mM mercaptoethanol (Sigma-Aldrich, St. Louis, Mo.),and 4 ng/mL human recombinant FGF2 (Invitrogen)].

While the medium was replaced every day, the undifferentiated stem cells(FIG. 2A) were passaged at a ratio of 1:12 to 1:15 every six or sevendays manually or with collagenase IV (Invitrogen), and then transferredonto fresh mouse embryonic fibroblast feeder cells. During the passageof the human induced pluripotent stem cells, immunochemical staining(FIGS. 2B and 2C) with alkaline phosphatase (Sigma-Aldrich), NANOG(Abcam, Cambridge, Mass.) and SSEA-4 (Chemicon, Temecula, Calif.), whichare antigens specific to undifferentiated human induced pluripotent stemcells, was conducted at regular intervals of time to monitor the degreeof differentiation. Cells that were identified to have undergonedifferentiation were removed. To evaluate pluripotency of theundifferentiated human induced pluripotent stem cells, a teratoma assaywas performed. 10 weeks after transplantation of 1×10⁷ of human inducedpluripotent stem cells into the dorsal surface of an immunosuppressedmodel, rd/SCID mouse, teratomas thus formed were removed, followed byH&E staining (FIG. 2D).

The presence of mycoplasma contamination in the human inducedpluripotent stem cells, which could have an undesirable effect on thedifferentiation of human induced pluripotent stem cells, was regularlymonitored using a MycoAlert mycoplasma detection kit (Lonza, Rockland,Me.).

Example 2: Differentiation from Human Embryonic Stem Cells or HumanInduced Pluripotent Stem Cells into Eye Field Precursors

First, human embryonic stem cells or human induced pluripotent stemcells cultured by the method of Example 1 were separated from the mouseembryonic fibroblasts and transferred onto 6-well ultra-low attachmentplates (Corning Incorporated, Corning, N.Y., USA), respectively.

To the human embryonic stem cells or human induced pluripotent stemcells in the 6-well ultra-low attachment plates was added a medium forinducing differentiation into eye field precursors [DMEM/F12, 10%KnockOut serum replacement, 1 mM L-glutamine, 0.1 mM nonessential aminoacids, 0.1 mM mercaptoethanol, 1% B27 supplement (Invitrogen), 1 ng/mLrecombinant Noggin (R&D Systems), 1 ng/mL recombinant Dkk-1 (recombinantDickkopf-1, R&D Systems), and 5 ng/mL recombinant IGF-1 (recombinantinsulin-like growth factor-1, R&D Systems)]. While the medium wasaspirated at 3 days and then replaced with a fresh medium, the cellswere cultured for 4 days to 5 days to generate eye field precursors inthe form of floating aggregates in the medium (FIGS. 1B, 3).

Example 3: Differentiation from Eye Field Precursors into RetinalProgenitor Cells

The eye field precursors (floating aggregates) generated in Example 2were seeded at a density of 53±8 cells per well (292±53 cells/floatingaggregate) into 6-well poly-D-lysine/laminin-coated plates (BDBiosciences), at a density of 30±5 cells per well on 12-wellpoly-D-lysine/laminin-coated plates, and at a density of 12±4 cells perwell on 8-well poly-D-lysine/laminin-coated plates, and then culturedfor 10 days to generate retinal progenitor cells (FIG. 1C), with thesupply of a medium for inducing differentiation into retinal progenitorcells [DMEM/F12 (Invitrogen), 1 mM L-glutamine (Invitrogen), 0.1 mMnonessential amino acids (Invitrogen), 0.1 mM mercaptoethanol(Sigma-Aldrich), 1% B27 supplement, 1% N2 supplement (Invitrogen), 10ng/mL Dkk-1, 10 ng/mL Noggin, 10 ng/mL IGF-1, and 5 ng/mL FGF2](Protocol A) (FIGS. 3 and 4). Protocol B (FIG. 5) and C (FIG. 6) wereperformed by supplying the present medium for 7 days.

Example 4: Differentiation from Retinal Progenitor Cells into ImmatureRetinal Ganglion Cells (RGCs)

The retinal progenitor cells generated in Example 3 were cultured in amedium for inducing differentiation into immature retinal ganglion cells[DMEM/F12(Invitrogen), 1 mM L-glutamine (Invitrogen), 0.1 mMnonessential amino acids (Invitrogen), 0.1 mM mercaptoethanol(Sigma-Aldrich), 1% B27 supplement (Invitrogen), 1% N2 supplement(Invitrogen), 10 ng/mL Noggin, 10 ng/mL IGF-1, 5 ng/mL FGF2, 50 ng/mLrecombinant Wnt3a (recombinant Wnt3a, R&D Systems)] for 3 days, thusgiving immature retinal ganglion cells (FIGS. 1D, 3 to 5). Protocol Cwas performed by supplying the present medium for 6 days (FIG. 6).

Example 5: Differentiation from Immature Retinal Ganglion Cells intoMature Retinal Ganglion Cells: Step 1

The immature retinal ganglion cells generated in Example 4 were inducedto differentiate into mature retinal ganglion cells by supplying adifferentiation medium [DMEM/F12 (Invitrogen), 1 mM L-glutamine(Invitrogen), 0.1 mM nonessential amino acids (Invitrogen), 0.1 mMmercaptoethanol (Sigma-Aldrich), 1% B27 supplement (Invitrogen), 1% N2supplement (Invitrogen), 10 ng/mL IGF-1, 250 ng/mL recombinant Shh(recombinant Sonic Hedgehog amino terminal peptide, Shh, R&D Systems)]for 5 days (FIG. 1E, 3 to 6).

Example 6: Differentiation from Immature Retinal Ganglion Cells intoMature Retinal Ganglion Cells: Step 2

The retinal ganglion cells generated in Example 5 were matured bysupplying a differentiation medium [DMEM/F12 (Invitrogen), 1 mML-glutamine (Invitrogen), 0.1 mM nonessential amino acids (Invitrogen),0.1 mM mercaptoethanol (Sigma-Aldrich), 1% B27 supplement (Invitrogen),1% N2 supplement (Invitrogen), 10 ng/mL IGF-1, 250 ng/mL Shh, 500 nMall-trans retinoic acid (RA, Sigma-Aldrich)] for 17 days (FIG. 1E, 3 to6). All the media of Examples 2 to 6 were replaced with fresh ones everytwo or three days, and the cells were cultured at 37° C. in a 5% CO₂atmosphere (FIG. 1F, 3 to 6). The present medium for retinal ganglioncells was used to culture the cells until day 120 of differentiation.

Example 7: Assay for Cellular Differentiation-Related Markers

<7-1> Immunochemical Staining and Identification of CellularDifferentiation-Related Marker Protein Expression

The differentiation of the cells obtained in Examples 3 to 6 wasexamined using an immunochemical staining method as follows.

The eye field precursors (floating aggregates) were cultured in 8-wellpoly-D-lysine/laminin-coated slides (BD Biosciences, Bedford, Mass.)under the same conditions that were used for differentiation into theretinal progenitor cells, the immature retinal ganglion cells, and themature retinal ganglion cells. The cells completely cultured in eachstep were fixed with 4% paraformaldehyde (Sigma-Aldrich), after whichnon-specific reactions were blocked with PBS containing 3% BSA (JacksonImmunoresearch Laboratory, Bar Harbor, Me., USA) and 0.25% Triton X-100(Sigma-Aldrich).

After being blocked for 90 min, the slides in each differentiation stepwere incubated overnight at 4° C. with antibodies specific to cells ofeach differentiation step as given in Table 1. Before use, theseantibodies were diluted in a PBS solution containing 1% BSA and 0.25%Triton X-100. The cells cultured on the slides in each step were washedthree times for 5 min with PBS and incubated at room temperature for 2hr with species-specific secondary antibody conjugated with Cy3 (1:800,Jackson Immunoresearch Laboratory) or Alexa488 (1:500, Invitrogen)(Table 1). A standard material suitable for the primary and thesecondary antibodies was used to examine non-specific staining orinteraction between the antibodies. Thereafter, the cells were washedthree times for 5 min with PBS, counterstained with DAPI(4′,6-diamidino-2 phenylindole) and mounted in Vectashield (VectorLaboratories), followed by visualization under an epifluorescencemicroscope (Nikon Eclipse, E800, Tokyo, Japan) and a confocal microscope(Zeiss LSM510, Carl Zeiss, Inc, Thornwood, N.Y., USA). 500 cells werecounted from 20 microscopic fields randomly selected at 400magnification and evaluated for positive responses to each antibody.Positive responses to antibodies were determined after at least threeevaluations.

<7-2> Flow Cytometry and Identification of CellularDifferentiation-Related Marker Protein Expression

Cells were detached by 0.05% trypsin (Invitrogen) on days 17 and 39after induction of differentiation. Cells were fixed with aCytofix/Cytoperm buffer solution (Biosciences), and washed with aPerm/Wash buffer solution (BD Biosciences). Cells were reacted withprimary antibody at 4° C. for 30 min, and secondary antibody at 4° C.for 20 min (Table 1). The reaction samples were analyzed by FACSCalibur(BD Biosciences) and FlowJo software (Treestar).

<7-3> Identification of Retinal Ganglion Cell-Specific Marker by WesternBlotting

The cultured cells were lysed on day 39 after induction ofdifferentiation with a protein extraction buffer solution containing aprotease inhibitor. Total protein concentration was measured using aBradford protein assay kit. An equal amount of the protein was loaded onpolyacrylamide gel (Any kD Mini-PROTEAN TGX precast polyacrylamide gels,Bio-Rad, Hercules, Calif.), and then transferred onto a polyvinylidenedifluoride membrane (Milipore, Billerica, Mass.). This membrane wasreacted with primary antibody (Table 1, Brn3B 1:1,000, Brn3A 1:1,000,Tuj1 1:1000, NF200 1:1,000, Actin 1:2,000) and secondary antibody(HRP-conjugated secondary antibody, Goat anti-mouse or anti-rabbit IgG,diluted 1:2,000, Santa Cruz, Calif.), and then the reacted proteins weredetected using chemiluminescence detection kit (Amersham ECL, GEHealthcare Life technology, Piscataway, N.J.).

TABLE 1 Antibodies used in immunofluorescence assay Dilution forCatalogue Antibody Species ICF* Supplier No. Brn3A Rabbit 1:500 giftfrom Eric N/A Turner Brn3B Rabbit 1:500 gift from Eric N/A TurnerIslet-1 Mouse 1:10 DSHB 40.2D6 KI67 Mouse 1:200 Vector vp-k452Laboratories Map2 Mouse 1:1,000 Sigma-Aldrich M1406 Map2 Rabbit 1:500Milipore AB5622 Math5 Rabbit 1:500 Abcam ab78046 Nanog Rabbit 1:500Abcam ab80892 Neurofilament- Rabbit 1:1,000 Sigma-Aldrich N4142 200NMDAR1 Mouse 1:250 BD Bio- 556308 sciences Pax6 Mouse 1:1 DSHB PAX6PSD-95 Mouse 1:500 NeuroMab 75-028 Rax Rabbit 1:250 Abcam ab23340 SSEA4Mouse 1:100 Chemicon MAB4304 Synapsin1 Rabbit 1:500 Stressgen VAP-SV060E Thy-1.2 Mouse 1:250 eBioscience 14-0903-81 TrkB Mouse 1:100 SantaCruz sc-136991 β-tubulin Mouse 1:1,000 Covance MMS-435P (Tuj1) VgatRabbit 1:1,000 Synaptic 131 003 Systems Vglut1 Rabbit 1:1,000 Synaptic135 303 Systems Anti-mouse Alexa Goat 1:500 Molecular A11029 Fluor 488Probes Anti-rabbit Alexa Goat 1:500 Molecular A11034 Fluor 488 ProbesAnti-mouse Cy3 Goat 1:800 Jackson 115-165- Laboratory 062 Anti-rabbitCy3 Goat 1:800 Jackson 111-165- Laboratory 045 Anti-mouse R- Goat 1:800Jackson 115-116- Phycoerythrin Laboratory 146 Anti-rabbit R- Goat 1:800Jackson 115-116- Phycoerythrin Laboratory 144 *ICF:Immunocytofluorescence staining

As a result of identifying differentiation-related marker expression,flow cytometry results (Table 2A) of markers of cells obtained byProtocol A of Example 4 on day 17 after induction of differentiationshowed that retinal progenitor cell markers, Rax- and Pax6-positivecells were 95.8±1.4% and 93.8±0.7%, respectively (FIG. 7A). Meanwhile,retinal ganglion cell-specific markers, Math5, Brn3B- and Brn3A-positivecells were 95.2±1.2%, 96.8±0.6%, and 97.5±0.9%, respectively. In mice,Math5, which is expressed at an early stage of retinal ganglion cells,is known to be detected from embryonic day (E) 11 to 1 day after birth,and Brn3B and Brn3A are known to be detected at a time of retinalganglion cell generation during embryonic development and continue fortheir life. Further, these markers are co-expressed in most retinalganglion cells. Islet-1, which is a marker of the subtype of retinalganglion cells, was detected as 16.4±2.7%. On day 17 after induction ofdifferentiation, the immunofluorescence staining results and positiverates are consistent with the results of flow cytometry. In nuclei ofmost cells, Math5 and Brn3B were strongly stained (FIGS. 7B and 7C). Thecytoplasm of Brn3A (nuclear staining)-positive cells are positive toneuron-specific marker Tuj1 (98.2±0.4%) (Table 2A, FIG. 7D), indicatingtheir differentiation into retinal ganglion cells, which are a type ofneuron. About ⅕ of the cells positive to NF200 which is expressed inaxons of retinal ganglion cells were positive to Islet-1, which is amarker of the subtype of retinal ganglion cells (Table 2A, FIG. 7E). 1/3of the total retinal ganglion cells are reported to be Islet-1-positiveretinal ganglion cells. Maturation characteristics of axonal anddendritic arbor, ring, and spiny process were not observed yet.

Flow cytometry results (Table 2B, FIG. 8) of markers of cells obtainedby Protocol A of Example 6 on day 39 after induction of differentiationshowed that Pax6-positive cells were 82.3±3.5%. Pax6 is known to beexpressed in retinal progenitor cells and also to continue to beexpressed after differentiation into retinal ganglion cells (FIG. 9A).Math5-, Brn3B (FIGS. 9B, 9F, 9G)-, and Brn3A (FIGS. 9C, 9D, 9H)-positivecells were 77.3±2.7%, 84.7±0.8%, 89.9±2.3%, respectively. It seems thatMath5 was reduced with cell differentiation. Islet-1-positive cells were16.4±2.7% on day 17 after induction of differentiation and increased to32.8±7.1% on day 39 after induction of differentiation, indicating that1/3 of the total retinal ganglion cells are Islet-1-positive (FIG. 9E).Meanwhile, cell proliferation marker KI67-positive cells were remarkablyreduced from 81.0±3.5% to 18.4±3.5% on day 17 after induction ofdifferentiation. The immunofluorescence staining results showed thataxonal ring and spiny process, and dendritic arbor, ring, and spinyprocess were observed in retinal ganglion cells, indicating maturation(FIGS. 9F to 9I). This maturation further progressed on day 59 afterinduction of differentiation (FIG. 10).

Results of Western blot analysis also showed strong expressions ofretinal ganglion cell-specific markers, Brn3B and Brn3A andneuron-specific markers, NF200 and Tuj1, as in the results ofimmunochemical staining and flow cytometry (FIG. 9J).

TABLE 2 Flow cytometry results of H9-derived RGC on days 17 and 39 afterdifferentiation according to Protocol A A) day 17 B) day 39 Marker Mean,%(n = 3) SEM Marker Mean, %(n = 3) SEM Brn3A 97.5 0.9 Brn3A 89.9 2.3Brn3B 96.8 0.6 Brn3B 84.7 0.8 Islet-1 16.4 2.7 Islet-1 32.8 7.1 KI6781.0 3.5 KI67 18.4 3.5 Math5 95.2 1.2 Math5 77.3 2.7 NF200 98.3 0.4NF200 96.5 0.9 Pax6 93.8 0.7 Pax6 82.3 3.5 Tuj1 98.2 0.4 Tuj1 94.7 2.5Rax 95.8 1.4

On day 39 after induction of differentiation into retinal ganglion cellsaccording to Protocol B (FIG. 5) and Protocol C (FIG. 6) of Examples 5and 6, marker protein expressions were identified. The results of flowcytometry of cell markers (Tables 3A and 3B) showed that cells positiveto retinal ganglion cell-specific markers, Math5, Brn3B and Brn3A andneuronal axon and dendrite markers, Tuj1 and NF200 were similar to thoseof the prototype Protocol A, but the subtype marker Islet-1-positivecells were reduced to 12.4±2.5% and 7.8±1.6% in Protocols B and C. Onthe other hand, cytomorphology was examined by immunofluorescencestaining. As a result, cells differentiated according to Protocol Bshowed positive rates of axons and dendrites and maturity being similarto those of the cells according to Protocol A, but low positive rates ofpresynaptic and postsynaptic vesicles having electrical functions,compared to Protocol A (FIG. 11). Cells differentiated according toProtocol C showed active generation of presynaptic and postsynapticvesicles, but relatively low maturity of axon and dendrites (FIG. 12).

TABLE 3 Flow cytometry results of H9-derived RGC on day 39 afterdifferentiation according to Protocols B and C A) Protocol B B) ProtocolC Marker Mean, %(n = 3) SEM Marker Mean, %(n = 3) SEM Brn3A 89.8 5.0Brn3A 91.6 1.0 Brn3B 83.3 1.5 Brn3B 86.0 2.4 Islet-1 12.4 2.5 Islet-17.8 1.6 KI67 15.0 1.0 KI67 15.9 4.7 Math5 93.6 1.1 Math5 91.0 1.9 NF20089.6 3.8 NF200 94.1 1.7 Pax6 80.1 4.7 Pax6 75.7 3.9 Tuj1 94.1 1.8 Tuj195.6 0.5

Human embryonic stem cell line H7, other than H9, and human inducedpluripotent stem cells were differentiated into retinal ganglion cellsaccording to Protocol A of Example 6. On day 39 after induction ofdifferentiation, immunofluorescence staining of the cell markers andflow cytometry were performed. As a result, percentages of Math5-,Brn3B- and Brn3A-positive human embryonic stem cell H7 were 95.0%, 90.2%and 94.4%, respectively, which are the same as in H9 cell line (Table4A). Immunofluorescence staining results showed mature features of axonsand dendrites and active generation of presynaptic and postsynapticvesicles having electrical functions (FIG. 13).

Percentages of Math5-, Brn3B- and Brn3A-positive human inducedpluripotent stem cell were 73.0%, 61.4% and 77.0%, respectively, whichare relatively lower than in H9 cell line (Table 4B). Immunofluorescencestaining results showed mature features of axons and dendrites andactive generation of presynaptic and postsynaptic vesicles havingelectrical functions (FIG. 14).

TABLE 4 Flow cytometry results of H7 and iPSC-derived RGC on day 39after differentiation according to Protocol A A) H7-derived RGCs B)iPSC-derived RGCs Marker Mean, %(n = 2) Marker Mean, %(n = 2) Brn3A 94.4Brn3A 77.0 Brn3B 90.2 Brn3B 61.4 Islet-1 17.8 Islet-1 12.0 KI67 29.1KI67 25.4 Math5 95.0 Math5 73.0 NF200 95.5 NF200 87.5 Pax6 87.8 Pax656.2 Tuj1 90.5 Tuj1 89.0

Example 8: Test of Electrophysiological Properties and Functions ofRetinal Ganglion Cells Differentiated from Human Pluripotent Stem Cells

Whole-cell voltage recordings and current-clamp recordings wereperformed at 32±1° C. by infusing a recording chamber with artificialcerebrospinal fluid at a rate of 1 mL/min to 1.5 mL/min. The artificialcerebrospinal fluid was composed of 125 mM NaCl, 25 mM NaHCO₃, 2.5 mMKCl, 1.25 mM NaH₂PO₄, 2 mM CaCl₂, 1 mM MgCl₂, 20 mM glucose, 1.2 mMpyruvate and 0.4 mM Na-ascorbate, and saturated at pH 7.4 with 95% O₂and 5% CO₂. A patch pipette having a tip resistance of 3.5 MΩ to 4.5 MΩwas used. A series resistance after whole-cell configuration was between10 MΩ and 15 MΩ. Recordings were performed using an EPC-10 amplifier(HEKA, Lambrecht-Pfalz, Germany), and upon recording, a pipette solutioncontaining 143 mM K-gluconate, 7 mM KCl, 15 mM HEPES, 4 mM MgATP, 0.3 mMNaGTP, 4 mM Na-ascorbate and 0.1 mM EGTA was used, and pH was adjustedto 7.3 using KOH. Spontaneous excitatory postsynaptic currents (sEPSCs)were recorded at a holding potential of −70 mV. To identify the patternsof spontaneous postsynaptic current,6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 50 μM),D-(−)-2-amino-5-phosphonopentanoic acid (AP5, 50 μM) and (+)-bicuculline(50 μM) were injected to a bath solution of the experimental chamber(Sigma-Aldrich). CNQX blocks AMPA receptor, AP5 blocks NMDA receptor,and bicuculline blocks GABA receptor. Na⁺ currents were blocked bytetrodotoxin (TTX, 1 μM), and K⁺ currents were blocked by4-aminopyridine (4-AP, 1 mM) (Sigma-Aldrich).

<8-1> Test of Electrophysiological Properties of Retinal Ganglion CellsDifferentiated from Human Pluripotent Stem Cells

To test electrical properties of the human pluripotent stem cell-derivedretinal ganglion cells differentiated according to the presentinvention, retinal ganglion cells differentiated according to Protocol Awas first evaluated. In the evaluation of action potentials on day 39after induction of differentiation, a robust regular-spiking train ofaction potentials was observed in response to step current injection(FIG. 15A). The results of whole-cell patch clamp recording showed thepresence of voltage-gated sodium channel, which was blocked bytetrodotoxin (FIG. 15B). Therefore, it was confirmed that humanpluripotent stem cell-derived retinal ganglion cells were differentiatedinto electrically excitable cells. In the evaluation of actionpotentials on day 59 after induction of differentiation, actionpotentials were found to be more mature in response to step currentinjection than those on day 39 after induction of differentiation (FIG.16B). It was reported that during embryological development, neuronsdevelop into mature firing cells over days. An identical process isfound in vivo (Connors et al. 1982; McCormick & Prince, 1987). Similarresults are also observed in retinal ganglion cells differentiatedaccording to Protocols B (FIG. 17A) and C (FIG. 18A) and human inducedpluripotent stem cells (FIG. 20). The retinal ganglion cellsdifferentiated according to the protocol of the present invention showedincreased electrical maturation and function over time.

<8-2> Test of Electrophysiological Functions of Retinal Ganglion CellsDifferentiated from Human Pluripotent Stem Cells

Retinal ganglion cells differentiated from human pluripotent stem cellsaccording to the present invention form functional excitatory synapses.Synaptogenesis is a critical step in the development of neural networks.The formation of physical synapses among human pluripotent stemcell-derived retinal ganglion cells was detected using super-resolutionmicroscopy to visualize presynaptic and postsynaptic proteinlocalization. Synapses were defined as regions of hundreds of nanometersin diameter found near dendrites detected by MAP2 staining whereproteins specific to the pre- and postsynaptic compartments werejuxtaposed. Antibodies against presynaptic and postsynaptic proteinswere used to identify synapses: Antibodies against the excitatoryglutamatergic postsynaptic protein, PSD-95 (glutamatergic postsynapticdensity 95) and the presynaptic protein, synapsin1 were used. Foci ofPSD-95 generated from pluripotent stem cell-derived retinal ganglioncells were abundant along dendrites or in the 100 nm size range thereof,and juxtaposed, but non-overlapping, with presynaptic vesicle, synapsin1(FIGS. 10G and 10H). These are also found in retinal ganglion cellsderived from another human embryonic stem cell line H7 (FIGS. 13G and13H) and human induced pluripotent stem cells (FIGS. 14K and 14L),indicating formation of physical synapses among human pluripotent stemcell-derived retinal ganglion cells.

Meanwhile, physical synapses formed among the cells wereelectrophysiologically evaluated. Spontaneous excitatory postsynapticcurrents (sEPSCs) were detected without co-culture with other retinaltissues on day 39 after induction of differentiation from humanembryonic stem cell-derived retinal ganglion cells (FIG. 15C),indicating formation of functional excitatory synapses among humanembryonic stem cell-derived retinal ganglion cells. Further, frequencyof sEPSCs and depth of spiking were increased when evaluated on day 59after induction of differentiation (FIG. 16E), implying that neuronalmaturation progressed over time. The sEPSCs were found to be blocked byCNQX, suggesting that they are one of AMPA-mediated excitatoryglutamatergic neurons. Similar results are also observed in the retinalganglion cells differentiated according to Protocols B (FIG. 17B) and C(FIG. 18B).

Example 9: Comparison Between Protocols for Differentiation from HumanEmbryonic Stem Cells or Human Induced Pluripotent Stem Cells intoRetinal Photoreceptor Cells and Retinal Ganglion Cells

The present inventors disclosed a method of differentiating retinalcells from stem cells in the previous patents (Korean Patent NO.10-1268741 (2013 May 22) and WO2011/043591 (2011 Apr. 14)).

According to the methods disclosed in the above documents,differentiation of photoreceptor cells from retinal progenitor cells wasmaximized to about 80%. However, their differentiation into retinalganglion cells was partially progressed to only about 6%.

<9-1> Differentiation from Human Embryonic Stem Cells or Human InducedPluripotent Stem Cells into Retinal Photoreceptor Cells

Differentiation from human embryonic stem cells or human inducedpluripotent stem cells into eye field precursors and retinal progenitorcells was performed in the same manner as in Examples 1 to 3.

On day 13 after induction of differentiation, retinal progenitor cellsgenerated in Example 3 were differentiated into photoreceptor cellprecursors by supplying a differentiation medium for photoreceptor cellprecursors [DMEM/F12(Invitrogen), 1 mM L-glutamine (Invitrogen), 0.1 mMnonessential amino acids (Invitrogen), 0.1 mM mercaptoethanol(Sigma-Aldrich), 1% B27 supplement (Invitrogen), 1% N2 supplement(Invitrogen), 10 ng/mL Noggin, 10 ng/mL IGF-1, 5 ng/mL FGF2, 50 ng/mLrecombinant Wnt3a (recombinant Wnt3a, R&D Systems)] for 5 days. On day18 after induction of differentiation, 250 ng/mL recombinant Shh(recombinant Sonic Hedgehog amino terminal peptide, Shh, R&D Systems)was added to the differentiation medium for photoreceptor cellprecursors and the cells were differentiated for 5 days intophotoreceptor cells. On day 21 after induction of differentiation, 500nM retinoic acid (RA) was added to the medium for photoreceptor cells,and cultured for 29 days to mature the generated photoreceptor cells. Inthe case where culture of the photoreceptor cells was to continue after29 days, the medium containing Wnt3a, Shh and RA was continuouslysupplied. In the immunofluorescence results of the cells generated bythis method, photoreceptor cells were 80% or more and retinal ganglioncells were about 6%.

<9-2> Differentiation from Human Embryonic Stem Cells or Human InducedPluripotent Stem Cells into Retinal Ganglion Cells

Differentiation from human embryonic stem cells or human inducedpluripotent stem cells into retinal ganglion cells was performed in thesame manner as in differentiation into eye field precursors, anddifferentiation into retinal progenitor cells was performed in the samemanner as in differentiation into photoreceptor cells, except that 50ng/mL recombinant Wnt3a was supplied from day 14 after induction ofdifferentiation for 3 days, and then removed. Shh and RA were suppliedafter removal of Wnt3a. That is, after initiation of differentiationinto retinal ganglion cells, when retinal ganglion cells aredifferentiated and matured, a medium from which Wnt3a is removed and towhich Shh and RA are added at each stage is needed.

In the immunofluorescence results of the cells generated by this method,photoreceptor cell-related markers, Crx and Ret-P1, were not observed.

Example 10: Differentiation from Immature Retinal Ganglion Cells intoMature Retinal Ganglion Cells: Step 2

The mature retinal ganglion cells obtained in Example 6 can be maturedusing the differentiation method of Example 6, but they can be alsomatured using a medium prepared by removing IGF-1, Shh, and retinoicacid form the above differentiation medium on day 39 after induction ofthe differentiation. Electrophysiological analysis was performed on day96 after induction of the differentiation to evaluate maturity (FIG.19). In addition, retinal ganglion cells were matured on day 32 afterinduction of the differentiation in the same manner, and as a result,they showed similar maturity to those cultured in a medium containingall of IGF-1, Shh and retinoic acid.

Example 11: Differentiation of Human Embryonic Stem Cell-Derived RetinalGanglion Cells by Wnt Signaling Pathway Activator and Shh ReceptorActivator

Differentiation from human embryonic stem cells or human inducedpluripotent stem cells into eye field precursors or retinal progenitorcells was performed in the same manner as in Examples 1 to 3.

On day 14 after induction of differentiation, retinal progenitor cellsgenerated in Example 3 were cultured and differentiated into immatureretinal ganglion cells for 3 days in a differentiation medium [DMEM/F12(Invitrogen), 1 mM L-glutamine (Invitrogen), 0.1 mM nonessential aminoacids (Invitrogen), 0.1 mM mercaptoethanol (Sigma-Aldrich), 1% B27supplement (Invitrogen), 1% N2 supplement (Invitrogen), 10 ng/mL Noggin,10 ng/mL IGF-1, 5 ng/mL FGF2, 50 ng/mL recombinant Wnt3a (R&D Systems)]containing 2 μM BIO (6-bromoindirubin-3′-oxime) or 50 ng/mL Norrin asthe Wnt signaling pathway activator instead of 50 ng/mL recombinantWnt3a. On day 17 after induction of differentiation, immature retinalganglion cells thus generated were cultured and differentiated intomature retinal ganglion cells for 5 days in a differentiation medium[DMEM/F12 (Invitrogen), 1 mM L-glutamine (Invitrogen), 0.1 mMnonessential amino acids (Invitrogen), 0.1 mM mercaptoethanol(Sigma-Aldrich), 1% B27 supplement (Invitrogen), 1% N2 supplement(Invitrogen), 10 ng/mL IGF-1, 250 ng/mL recombinant Shh (R&D Systems)]containing 1 μM purmorphamine as the Shh receptor activator instead of250 ng/mL Shh. On day 22 after induction of differentiation, the matureretinal ganglion cells were matured for 39 days using a medium preparedby adding 500 nM retinoic acid (RA) to the above differentiation medium.

The immunofluorescence assay of the cells generated by this method wasperformed using retinal ganglion cell markers, Islet-1 and NF200, andthe results were consistent with the results of using Wnt3a and Shh(FIG. 21).

Example 12: Effects of Wnt3a, Shh, and RA Used in Protocol aDifferentiation Method

To examine effects of each of Wnt3a, Shh and RA used in the Protocol Adifferentiation method during production of retinal ganglion cells,respective factors were treated according to a differentiation scheduleof Protocol A, and on day 39 after induction of differentiation, animmunofluorescence assay was performed using retinal ganglioncell-specific markers (FIG. 22).

1 μg/mL of a Wnt3a antagonist, Dkk1 was treated instead of Wnt3a on days14 to 17 after induction of differentiation, and Shh and RA were treatedaccording to the differentiation schedule, followed byimmunofluorescence assay. As a result, retinal ganglion cells werehardly produced, because no Wnt3a was added and intrinsic Wnt3a ofretinal progenitor cells was inhibited by Dkk1 (all marker-positiverates: less than 2%) (FIG. 22 (A)).

When Shh and RA were treated according to the respective differentiationschedules without treatment of Wnt3a, a small number of retinal ganglioncells was produced by the effect of intrinsic Wnt3a of retinalprogenitor cells (all marker-positive rates: about 10% to 15%) (FIG. 22(B)).

When Wnt3a was only treated without treatment of Shh and RA, 80% or moreof retinal ganglion cells were produced due to the effect of Wnt3a.However, caliber growth and fasciculation of axons of retinal ganglioncells were delayed due to absence of shh (see NF200 staining). Further,no synaptogenesis and dendritic spine development of retinal ganglioncells were observed due to absence of RA (see TUJ1 staining) (FIG. 22(C)).

When Wnt3a and Shh were treated without treatment of RA, 80% or more ofretinal ganglion cells were produced due to the effect of Wnt3a, and theeffect of Shh was also observed. However, synaptogenesis and dendriticspine development of retinal ganglion cells were inhibited due toabsence of RA (see TUJ1 staining) (FIG. 22 (D)).

When Wnt3a and RA were treated without treatment of Shh, 80% or more ofretinal ganglion cells were produced due to the effect of Wnt3a, butcaliber growth and fasciculation of NF200-positive axons were delayeddue to absence of shh (see NF200 staining).

These results suggest that treatment of Wnt3a plays a critical role indifferentiation of retinal ganglion cells. It was also confirmed thatretinal ganglion cells can be well-differentiated when RA and Shh areproperly treated according to the schedule.

Example 13: Cell Line of Human Pluripotent Stem Cell-Derived RetinalGanglion Cells

Differentiation from stem cells into mature cells of organs requires along period of time, and relies on an expert's time and efforts, andmany reagents are needed. If cells at a final or intermediate stage ofdifferentiation are established as cell lines, such differentiation timecan be greatly reduced. That is, if mature cells are needed,differentiation is induced not from stem cells but from established celllines, thereby preparing mature cells for a short period of time. Withrespect to this purpose, the present inventors have attempted toestablish cell lines from mature cells at a final stage ofdifferentiation, and finally they succeeded. Differentiation of stemcells progresses with asymmetric division. That is, two daughter cellsgenerated after cell division have different cellular fates: one copy ofthe original stem cell as well as a second daughter programmed todifferentiate into a non-stem cell fate. The present invention ischaracterized in that secondary culture of differentiated mature cellsis performed to make mature differentiated cells die due toenvironmental change and to proliferate cells having stem cell features,leading to establishment of a cell line. In particular, it is animportant point to establish an intermediate-stage cell line having bothfeatures of the original differentiated cells and stem cells.

Cells were detached by 0.05% trypsin (Invitrogen) on day 32 or 39 afterinduction of differentiation. The obtained cells were seeded on aculture flask, dish, or plate containing one of the following media at adensity of 1.5×10⁴ to 1.6×10⁴/cm². The following two media (Medium 1 andMedium 2) were the same as each other in terms of cell proliferationcapacity, number and period of passage. Cells were cultured at 5% carbondioxide (CO₂) and 37° C. while the following media were replaced every 2days to 3 days. The proliferated cells were passaged at a ratio of 1:6to 1:10 every 3 days to 4 days with 0.05% trypsin treatment.

Medium 1: [IMDM (Invitrogen), 15% FBS, 1 mM L-glutamine (Invitrogen),0.1 mM mercaptoethanol (Sigma-Aldrich), 1%Insulin/Transferrin/Selenium-X (Invitrogen)].

Medium 2: [IMDM (Invitrogen), 15% FBS, 1 mM L-glutamine (Invitrogen),0.1 mM mercaptoethanol (Sigma-Aldrich), 5 ng/mL FGF2, 10 ng/mL IGF-1, 5ng/mL human recombinant EGF (human recombinant epidermal growth factorPeprotech, Rocky Hill, N.J.)].

Cells were cultured to passage number 20 (p20), and all cells passagedin Medium 1 and Medium 2 showed neuronal morphology in vitro (FIG. 23).Human pluripotent stem cell-derived retinal ganglion cell lines atpassage number 15 to 17 (p15 to p17) were used to evaluate theircellular characteristics and neuronal functions. Immunofluorescenceassay using antibodies against retinal ganglion cell-specific markerswas performed by the method of Example 7, and neuronal functions wereevaluated by Live Cell Ca²⁺ imaging.

For calcium imaging, cells cultured on 18 mm coverslip were washed withTyrode's solution (119 mM NaCl, 2.5 mM KCl, 2 mM CaCl₂, 2 mM MgCl₂, 25mM HEPES, 30 mM glucose, pH 7.4) twice or three times, and then culturedat 37° C. with addition of 1 μM Fluo-4-AM (Life technologies, Carlsbad,Calif., USA). After culturing for 15 min, cells were washed withTyrode's solution for 10 min. Time differential images were obtained byusing an Olympus IX-71 inverted microscope (Olympus, Tokyo, Japan)equipped with 40×(1.0 NA) oil lens and EMCCD (iXon887, AndorTechnologies, Belfast, Northern Ireland) every 0.5 sec for 30 min. Fromthe 10^(th) image frame, cells were stimulated with 1 mM glutamate.After stimulation, cells were infused with Tyrode's solution.

The results of immunofluorescence assay showed that ganglioncell-specific markers Math5 (98.9%), Brn3B (52.4%), and Brn3A (99.7%)were expressed, and functional markers Thy1.2 (86.1%), TrkB (44.0%), andNMDAR-1 (97.0%) were also expressed. A neuronal marker Tuj1 (100%), anda retinal ganglion cell axon marker NF200 (98.5%) were also stronglyexpressed. Meanwhile, a cell proliferation marker KI67 (49.2%) was alsoobserved, indicating that the cell line has cell proliferation capacity(FIG. 24).

Neuronal functions of the retinal ganglion cell line were tested byintracellular calcium images. The passaged cells were treated with 1 μMfluor-4 and stimulated with 1 mM glutamate. As a result, the majority oflive cells showed a considerable increase in cytoplasmic calcium levelsin response to glutamate stimulation, indicating that the retinalganglion cell line has neuronal functions (FIG. 25).

Based on the above description, it will be understood by those skilledin the art that the present invention may be implemented in a differentspecific form without changing the technical spirit or essentialcharacteristics thereof. Therefore, it should be understood that theabove embodiment is not limitative, but illustrative in all aspects. Thescope of the invention is defined by the appended claims rather than bythe description preceding them, and therefore all changes andmodifications that fall within metes and bounds of the claims, orequivalents of such metes and bounds are therefore intended to beembraced by the claims.

1. A method of preparing mature retinal ganglion cells bydifferentiation of stem cells into mature retinal ganglion cells,comprising: (a) culturing retinal progenitor cells in a mediumcomprising an IGF1R (insulin-like growth factor-1 receptor) activatorand a Wnt signaling pathway activator to differentiate them intoimmature retinal ganglion cells; and (b) culturing the immature retinalganglion cells in a medium whose composition does not comprise the Wntsignaling pathway activator from that of the medium of step (a).
 2. Themethod of claim 1, wherein the medium of step (a) comprises an IGF1Ractivator, a BMP (bone morphogenetic protein) signaling pathwayinhibitor, an FGF (fibroblast growth factor) signaling pathwayactivator, and a Wnt signaling pathway activator.
 3. The method of claim2, wherein step (b) comprises culturing the immature retinal ganglioncells in a medium whose composition does not comprise the BMP signalingpathway inhibitor, FGF signaling pathway activator, and Wnt signalingpathway activator, and comprises an Shh (sonic hedgehog) signalingpathway activator from that of the medium of step (a).
 4. The method ofclaim 3, further comprising a step (c) comprising culturing the immatureretinal ganglion cells in a medium whose composition includes RA(retinoic acid) from that of the medium of step (b).
 5. The method ofclaim 2, wherein step (b) comprises: (i) culturing immature retinalganglion cells in a medium whose composition does not comprise the Wntsignaling pathway activator from that of the medium of step (a); and(ii) culturing immature retinal ganglion cells in a medium whosecomposition does not comprise the BMP signaling pathway inhibitor andthe FGF signaling pathway activator, and comprises an Shh (sonichedgehog) signaling pathway activator from that of the medium of step(i).
 6. The method of claim 5, further comprising the step (c) ofculturing the immature retinal ganglion cells in a medium whosecomposition comprises RA (retinoic acid) from that of the medium of step(b)-(ii).
 7. The method of claim 4, further comprising a step (d)comprising culturing immature retinal ganglion cells or mature retinalganglion cells in a medium whose composition does not comprise one ormore selected from the group consisting of an IGF1R activator, an Shhsignaling pathway activator, and RA from that of the medium of step (c).8. The method of claim 1, wherein the retinal progenitor cells of step(a) are obtained by a method comprising: (a′) culturing stem cells in amedium comprising an IGF1R activator, a Wnt signaling pathway inhibitor,and a BMP signaling pathway inhibitor to differentiate them into eyefield precursors in the form of floating aggregates; and (b′) culturingthe eye field precursors of step (a′) in the form of floating aggregatesin a medium whose composition comprises an FGF signaling pathwayactivator from that of the medium of step (a′) to differentiate theminto retinal progenitor cells.
 9. The method of claim 8, wherein step(a′) is performed for about 1 day to 30 days, and step (b′) is performedfor about 5 days to 15 days.
 10. The method of claim 8, wherein the stemcells are selected from the group consisting of bone marrow stem cells(BMS), cord blood stem cells, amniotic fluid stem cells, fat stem cells,retinal stem cells (RSCs), intraretinal Muller glial cells, embryonicstem cells (ESCs), induced pluipotent stem cells (iPSCs), and somaticcell nuclear transfer cells (SCNTCs).
 11. The method of claim 1, whereinstep (a) is performed for about 1 day to 10 days, and step (b) isperformed for about 1 day to 120 days.
 12. A method of preparing matureretinal ganglion cells by differentiation of immature retinal ganglioncells into mature retinal ganglion cells, comprising culturing immatureretinal ganglion cells in a medium comprising an IGF1R (insulin-likegrowth factor-1 receptor) activator and an Shh (sonic hedgehog)signaling pathway activator.
 13. The method of claim 12, furthercomprising the step of culturing immature retinal ganglion cells in amedium whose composition comprises an IGF1R activator, an Shh signalingpathway and RA (retinoic acid).
 14. The method of claim 1, wherein theIGF1R activator is IGF-1 or IGF-2.
 15. The method of claim 1, whereinthe concentration of the IGF1R activator in the medium is about 0.01ng/mL to about 100 ng/mL.
 16. The method of claim 1, wherein the Wntsignaling pathway activator is one or more selected from the groupconsisting of Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6,Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, andWnt16b, substances increasing β-catenin levels; GSK3 (glycogen synthasekinase 3) inhibitors such as lithium, LiCl, bivalent zinc, BIO(6-bromoindirubin-3′-oxime), SB216763, SB415286, CHIR99021, QS11hydrate, TWS119, Kenpaullone, alsterpaullone, indirubin-3′-oxime, TDZD-8and Ro 31-8220 methanesulfonate salt; Axin inhibitors; APC (adenomatouspolyposis coli) inhibitors; norrin and R-spondin
 2. 17. The method ofclaim 16, wherein the concentration of the Wnt signaling pathwayactivator in the medium is 0.01 ng/mL to 500 ng/mL, except for LiCl, BIO(6-bromoindirubin-3′-oxime), and SB415286 among the Wnt signalingpathway activators in step (a), the concentration of LiCl in the mediumis about 0.1 mM to 50 mM, the concentration of BIO in the medium isabout 0.1 μM to 50 μM, and the concentration of SB415286 in the mediumis about 0.1 μM to 500 μM.
 18. (canceled)
 19. The method of claim 2,wherein the BMP signaling pathway inhibitor is one or more selected fromthe group consisting of Noggin, chordin, twisted gastrulation (Tsg),cerberus, coco, gremlin, PRDC (protein related to DAN and Cerberus), DAN(differential screening-selected gene aberrative in neuroblastoma),dante, follistatin, USAG-1 (uterine sensitization-associated gene 1),dorsomorphin and sclerostin.
 20. The method of claim 2, wherein theconcentration of the BMP signaling pathway inhibitor in the medium is0.01 ng/mL to 100 ng/mL.
 21. The method of claim 2, wherein the FGFsignaling pathway activator is one or more selected from the groupconsisting of FGF1, FGF2, FGF4, FGF8, FGF9, FGF17 and FGF19.
 22. Themethod of claim 2, wherein the concentration of the FGF signalingpathway activator in the medium is 0.01 ng/mL to 100 ng/mL.
 23. Themethod of claim 3, wherein the Shh signaling pathway activator is one ormore selected from the group consisting of Shh, Smo (smoothened)receptor activators, inhibitors of Smo inhibition by Ptc (Patched),substances increasing Ci/Gli family levels, inhibitors of theintracellular degradation of Ci/Gli proteins, and Shh receptoractivators such as Hg—Ag and purmorphamine.
 24. The method of claim 3,wherein the concentration of the Shh signaling pathway activator in themedium is about 0.1 ng/mL to 5000 ng/mL.
 25. The method of claim 4,wherein the concentration of RA in the medium is about 0.5 nM to about10,000 nM.
 26. The method of claim 8, wherein the Wnt signaling pathwayinhibitor is one or more selected from the group consisting of Dkk-1,Dkk-2, Dkk-3 and Dkk-4.
 27. The method of claim 8, wherein theconcentration of the Wnt signaling pathway inhibitor in the medium isabout 0.01 ng/mL to about 10,000 ng/mL.
 28. The method of claim 1,further comprising the step of determining whether the differentiatedcells are differentiated into the desired mature retinal ganglion cells.29. The method of claim 28, wherein the differentiation into matureretinal ganglion cells is determined by measuring mRNA or proteinexpression levels of one or more genes selected from the groupconsisting of Brn3B, Brn3A, Islet-1, NF200, Tuj1, Thy1.2, TrkB, NMDAR1,Map2, Vglut1, PSD-95, Synaptophysin, and Synapsin1.
 30. The method ofclaim 8, wherein the eye field precursors in the form of floatingaggregates of step (b′) are cultured adhering to a plate coated with anextracellular matrix selected from the group consisting ofpoly-D-lysine, laminin, poly-L-lysine, matrigel, agar, polyornithine,gelatin, collagen, fibronectin and vitronectin.
 31. (canceled)
 32. Themethod of claim 8, wherein the medium of step (a′) further comprisesDMEM/F12, 10% KnockOut serum replacement, and 1% B27 supplement, and themedium of step (b′) further comprises DMEM/F12, about 1% B27 supplement,and about 1% N2 supplement.
 33. The method of claim 1, wherein themedium of step (a) and (b) further comprises DMEM/F12, about 1% B27supplement, and about 1% N2 supplement.
 33. The method of claim 1,wherein the immature retinal ganglion cells express (i) one or moregenes selected from the group consisting of Brn3B, Brn3A, Islet-1, NF200and Tuj1, and (ii) Math5 gene.
 35. The method of claim 1, wherein themature retinal ganglion cells obtained by the method account for 60% to95% or more of the whole cell.
 36. A method of screening for a deathinhibitor or a proliferation promoter of mature retinal ganglion cells,comprising: (a) treating the isolated mature retinal ganglion cellsobtained by the method of claim 1 with a candidate for death inhibitionor proliferation promotion of the mature retinal ganglion cells; and (b)determining that the candidate is a death inhibitor or a proliferationpromoter of mature retinal ganglion cells when the candidate inhibitsdeath of the mature retinal ganglion cells or promotes proliferation ofthe mature retinal ganglion cells, respectively, compared to anon-candidate-treated group.
 37. The method of claim 36, wherein thedeath inhibitor or the proliferation promoter of mature retinal ganglioncells is a therapeutic agent for glaucoma or optic neuropathy.
 38. Amature retinal ganglion cell obtained by the method of claim 1, whereinthe cell exhibits one or more of the following features, compared topre-differentiative retinal progenitor cells: (1) an increasedexpression level of Brn3B, (2) an increased expression level of Brn3A;(3) an increased expression level of Islet-1, (4) an increasedexpression level of NF200; (5) an increased expression level of TuJ1,(6) an increased expression level of Thy1.2, (7) an increased expressionlevel of TrkB, (8) an increased expression level of NMDAR1; (9) anincreased expression level of Map2; (10) an increased expression levelof Vglut1; (11) an increased expression level of PSD-95; (12) anincreased expression level of Synaptophysin; and (13) an increasedexpression level of Synapsin1.
 39. A kit of screening for a deathinhibitor or a proliferation promoter of mature retinal ganglion cells,comprising the mature retinal ganglion cell of claim
 38. 40. The kit ofclaim 39, wherein the kit is used for screening of a therapeutic agentfor glaucoma or optic neuropathy.
 41. A pharmaceutical composition forthe treatment of glaucoma or optic neuropathy, comprising the matureretinal ganglion cell of claim
 38. 42. A method of treating glaucoma oroptic neuropathy including the step of administering the mature retinalganglion cell of claim 38 to a subject suspected of having glaucoma oroptic neuropathy.
 43. A method of preparing a mature retinal ganglioncell line, comprising: (a) culturing retinal progenitor cells in amedium comprising an IGF1R (insulin-like growth factor-1 receptor)activator and a Wnt signaling pathway activator to differentiate theminto immature retinal ganglion cells; and (b) culturing the immatureretinal ganglion cells in a medium whose composition does not comprisethe Wnt signaling pathway activator from that of the medium of step (a).44. The method of claim 43, wherein the medium of step (b) furthercomprises an Shh signaling pathway activator or RA (retinoic acid), orboth.
 45. The method of claim 43, further comprising separating thecultured immature retinal ganglion cells, and then culturing the cellsin (i) a medium comprising IMDM (Iscove's Modified Dulbecco's Media),L-glutamine, mercaptoethanol and insulin/transferrin/selenium-X, or (ii)a medium comprising IMDM (Iscove's Modified Dulbecco's Media),L-glutamine, mercaptoethanol, FGF2, IGF-1 and EGF.
 46. The method ofclaim 12, wherein the IGF1R activator is IGF-1 or IGF-2.
 47. The methodof claim 12, wherein the concentration of the IGF1R activator in themedium is 0.01 ng/mL to 100 ng/mL.
 48. The method of claim 8, whereinthe BMP signaling pathway inhibitor is one or more selected from thegroup consisting of Noggin, chordin, twisted gastrulation (Tsg),cerberus, coco, gremlin, PRDC (protein related to DAN and Cerberus), DAN(differential screening-selected gene aberrative in neuroblastoma),dante, follistatin, USAG-1 (uterine sensitization-associated gene 1),dorsomorphin and sclerostin.
 49. The method of claim 8, wherein theconcentration of the BMP signaling pathway inhibitor in the medium is0.01 ng/mL to 100 ng/mL.
 50. The method of claim 8, wherein the FGFsignaling pathway activator is one or more selected from the groupconsisting of FGF1, FGF2, FGF4, FGF8, FGF9, FGF17 and FGF19.
 51. Themethod of claim 8, wherein the concentration of the FGF signalingpathway activator in the medium is 0.01 ng/mL to 100 ng/mL.
 52. Themethod of claim 12, wherein the Shh signaling pathway activator is oneor more selected from the group consisting of Shh, Smo (smoothened)receptor activators, inhibitors of Smo inhibition by Ptc (Patched),substances increasing Ci/Gli family levels, inhibitors of theintracellular degradation of Ci/Gli proteins, and Shh receptoractivators such as Hg—Ag and purmorphamine.
 53. The method of claim 12,wherein the concentration of the Shh signaling pathway activator in themedium is 0.1 ng/mL to 5000 ng/mL.
 54. The method of claim 13, whereinthe concentration of RA in the medium is 0.5 nM to 10,000 nM.